NL2019801B1

NL2019801B1 - Delivery vectors

Info

Publication number: NL2019801B1
Application number: NL2019801A
Authority: NL
Inventors: Papadopoulou Panagiota; Campbell Frederick; Bussmann Jeroen; Kros Alexander; Arias Alpízar Gabriela
Original assignee: Univ Leiden
Priority date: 2017-10-25
Filing date: 2017-10-25
Publication date: 2019-05-02
Also published as: WO2019083365A1

Abstract

Novel |iposomes and |iposome compositions are provided herein. Corresponding kits and methods of making the |iposomes are also described. The |iposomes provide a useful means for selective delivery of a cargo such as an active pharmaceutical ingredient or an imaging agent to the blood brain barrier (BBB) of a subject. The |iposomes may be used for therapeutic, or diagnostic, such as for theranostic purposes.

Description

Delivery vectors

Novel liposomes and liposome compositions are provided herein. Corresponding kits and methods of making the liposomes are also described. The liposomes provide a useful means for selective delivery of a cargo such as an active pharmaceutical ingredient or an imaging agent to the blood brain barrier (BBB) of a subject. The liposomes may be used for therapeutic, or diagnostic, such as for theranostic purposes.

BACKGROUND

Diseases of the brain and central nervous system (CNS) can have permanent and devastating consequences on the physical and social well-being of the affected individual.

In some cases, highly invasive surgery is required to correct the source of the problem or improve the symptoms of disease. Alternatively, or in addition, medication may be used to treat the cause or symptoms of disease.

Methods for effective administration of medicines to the blood brain barrier (BBB) and often onwards into the brain, are currently being investigated. To date, the focus has been on receptor-mediated ligand targeting (Oiler-Salvia, B.; Sanchez-Navarro, M.; Giralt, E.; Teixido, M. ‘Blood-brain barrier shuttle peptides: an emerging paradigm for brain delivery’ Chem.

Soc. Rev. 2016, 4690-4707), with the most promising ligands being cited as transferrin (Tf), insulin, angiopeptide and ApoE fragments, and glutathione, each of which target a well-known receptor. However, none of these receptors are exclusively expressed at the BBB. More recently, components of neurotropic viruses (e.g. rabies virus glycoprotein) have also been investigated. The humanised anti-VEGF monoclonal antibody bevacizumab (Avastin ®) has also been developed as a targeted treatment of brain cancer. However, recent randomized, double-blind, placebo-controlled clinical trials showed no overall improvement to patient survival rates following this treatment regime (Gilbert, M.R. et al. ‘A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma’ N. Engl. J.

Med. 2014, 699-708).

Systemic administration (e.g. by intravenous injection) is typically used to administer these types of medicament to a patient. However, unless the medicament is effectively delivered to the blood brain barrier, there is an increased risk of off-target effects, and an increased need for high doses. Unfortunately, for the potential treatments discussed above, the percentage of injected dose (%ID) reaching the brain is rarely provided in the literature. Direct quantification as to the efficiency of targeting for each of these treatments is therefore, in general, hard to gauge. A few examples have been provided in the literature where the %ID within the brain (and inclusive of the brain endothelium) has been directly quantified. For cTfRMAb-TNFR, a chimeric mAb that binds to the mouse TfR, it has been shown that approximately 1.4% of the injected dose reaches the brain (Boado RJ, Zhang Y, Wang Y, Pardridge WM. 2009. Engineering and expression of a chimeric trans- ferrin receptor monoclonal antibody for blood-brain barrier delivery in the mouse. Biotechnol. Bioeng. 102(4):1251-58; Sumbria RK, Zhou Q-H, Hui EK-W, Lu JZ, Boado RJ, Pardridge WM. 2013. Pharmacokinetics and brain uptake of an IgG-TNF decoy receptor fusion protein following intravenous, intraperitoneal, and subcutaneous administration in mice. Mol. Pharm. 10(4):1425-31; Zhou Q-H, Boado RJ, Hui EK-W, Lu JZ, Pardridge WM. 2011. Brain-penetrating tumor necrosis factor decoy receptor in the mouse. Drug Metab. Dispos. 39(1):71-76). In a separate study on HIRMAb (humanized mAb against the insulin receptor), a fully humanized mAb for the human insulin receptor, approximately 2% of the injected dose was found to reach the brain (Boado RJ, Zhang Y, Zhang Y, Pardridge WM. 2007. Humanization of anti-human insulin receptor antibody for drug targeting across the human blood-brain barrier. Biotechnol. Bioeng. 96(2):381-91; Lu JZ, Boado RJ, Hui EK-W, Zhou Q-H, Pardridge WM. 2011. Expression in CHO cells and pharmacokinetics and brain uptake in the rhesus monkey of an IgG-iduronate-2-sulfatase fusion protein. Biotechnol. Bioeng. 108(8): 1954-64; Boado RJ, Hui EK-W, Lu JZ, Pardridge WM. 2009. AGT-181: expression in CHO cells and pharmacokinetics, safety, and plasma iduronidase enzyme activity in Rhesus monkeys. J. Biotechnol. 144(2):135- 41). For Tf-conjugated to AuNPs it was found that merely 0.3% injected dose reaches the brain (Yu YJ, Zhang Y, Kenrick M, Hoyte K, Luk W, et al. 2011. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target. Sci. Transl. Med. 3(84):84ra44). These % ID figures demonstrate the low percentage of active pharmaceutical ingredient delivery to the brain when systemic administration is used.

Medicines may also be administered to a patient using liposomes. Liposomes (also known as lipid vesicles) are colloidal particles that are prepared from polar lipid molecules derived either from natural sources or chemical synthesis. The lipids form an oval, closed structure, wherein an external curved lipid biiayer forms around an aqueous core. Medicines and other cargo can be entrapped or embedded within the lipid biiayer, to reduce off-target toxicity, improve solubility and/or increase efficacy of the medicament.

Liposomes have become the most widely investigated nanoparticles for drug delivery applications (Sercombe, L. et al., Front. Pharmacol. 6, 286, (2015); Allen, T. M. et al., Adv. Drug. Deliv. Rev. 65, 36-48, (2013)). However, the only targeted, liposomal drug delivery technologies approved for clinical use remains the use of long-circulating, drug-filled liposomes passively targeting solid tumors via the enhanced permeability and retention (EPR) effect (for example Doxil® or Myocet®). The targeting efficiencies of these liposomes are typically <1% of the total injected dose (%I.D) (Wilhelm, S. etal. Analysis of nanoparticle delivery to tumours. Nat. Rev. Mater. 2016, 16014)).

There is a need for novel delivery vectors with improved targeting to the BBB.

SUMMARY OF THE INVENTION

The inventors have developed a novel liposome which selectively targets to the blood brain barrier (BBB) of embryonic zebrafish following systemic (intravenous) administration. Surprisingly, the inventors have found selective targeting to the BBB requires liposomes that are made up of two lipids that undergo phase separation in the liposome (see Figure 15). Remarkably, when combinations of lipids were used that did not undergo phase separation in the resultant liposome, the liposomes did not demonstrate selective targeting to the BBB.

The inventors have tested a range of different lipid combinations and molar ratios and have identified the lipid characteristics required for production of a liposome that targets to the BBB after systemic administration. They have also demonstrated that cargoes such as small molecule drugs (e.g. the cytotoxic drug, doxorubicin) as well as larger cargoes (e.g. Au nanoparticles) can be encapsulated within the novel liposomes. The inventors have therefore identified a new means for delivery of cargo to the blood brain barrier (BBB) of a subject.

In addition to improved targeting efficiency and, in contrast to existing ligand targeting strategies, the components of the novel liposomes are cheap and the liposomes are easy to make on a large scale.

The inventors have exemplified the invention in zebrafish. The zebrafish genome is 70% homologous to humans and crucially brain morphology, organization and expression of key markers for BBB function and integrity is conserved between these species. The invention is therefore equally relevant to the delivery of cargo to the BBB of other subjects and particularly to the delivery of cargo to the BBB of human subjects.

Accordingly, in one aspect, the invention provides a liposome comprising: a) a first lipid of Formula I:

wherein R1 and R2 are each independently selected from H, Cio-C3o-alkyl, Cw-C3o-alkenyl, Cw-C3o-alkynyl, C(0)-Cw-C3o-alkyl, C(0)-Cw-C3o-alkenyl and C(0)-Cio-C3o-alkynyl; R3 is independently selected from H, Cw-C3o-alkyl, Cw-C3o-alkenyl and Cw-C3o-alkynyl; wherein a single one of R1, R2 and R3 is H; X1 and X2 are each independently selected from -0-, -S- and -NR4-; X3 is independently selected from a bond, -0-, -S-, -NR4-, -C(0)-, -C(0)0-, -0C(0)-, -C(0)-NR4-, -NR4C(O)- and -0P(0)20-; wherein if R3 is Η, X3 is not a bond; R4 is independently selected from H and Ci-C4-alkyl; each n is an integer independently selected from 1 to 4, preferably 1 or 2; or a pharmaceutically acceptable salt thereof; and, b) a second lipid, wherein phase separation occurs between the first lipid and the second lipid in the liposome.

Suitably, the lipid of formula I may be a lipid of formula II:

wherein X3 is -NHC(O)- or -0C(0)-; wherein R1 and R2 are each independently selected from H, C(0)-Cw-C3o-alkenyl and C(0)-Cw-C3o-alkynyl; R3 is independently selected from H, Cw-C3o-alkenyl and Cw-C3o-alkynyl; wherein a single one of R1, R2 and R3 is H.

Suitably, the first lipid may be:

or a pharmaceutically acceptable salt, regioisomer or pharmaceutically acceptable salt of a regioisomer thereof.

Suitably, the second lipid may be a phospholipid, optionally having the following formula III:

wherein R5 and R6 are each independently selected from C(0)-Cw-C3o-alkyl, C(0)-Cw-C3o-alkenyl and C(O)-C io-C3o-alkynyl; and R7 is independently at each occurrence Ci-C4-alkyl.

Suitably, the phospholipid may be selected from any one of phosphatidylcholine (PC), phos-phatidylglycerol (PG), phosphatidylserine (PS), phosphatidylethanolamine (PE), phosphati-dylglycerides, phosphatidic acid (PA), phospholsphingolipids, or any combination thereof.

Suitably, the phospholipid may be a phosphatidylcholine (PC).

Suitably, the phosphatidylcholine (PC) may be selected from the group consisting of 1,2-didecanoyl-sn-glycero-3-phosphocholine (DDPC), 1,2-dierucoyl-s/i-glycero-3-phosphocho-line (DEPC), 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLOPC), 1,2-dilauroyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1-myristoyl-2-palmitoyl-sn-glycero-3-phosphocholine (MPPC), 1-myristoyl-2-stearoyl-sn-glycero-3-phos-phocholine (MSPC), 1-palmitoyl-2-myristoyl-sn-3-phosphocholine (PMPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1-palmitoyl-2-stearoyl-sn-glycero-3-phospho-choline (PSPC), 1-stearoyl-2-myristoyl- sn-glycero-3-phosphocholine (SMPC), 1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine (SOPC), 1-stearoyl-2-palmitoyl-sn-glycero-3-phospho-choline (SPPC), egg phosphatidylcholine (EPC), soy PC, hydro soy PC (HSPC), brain PC, heart PC, liver PC or any combination thereof.

Suitably, the phospholipid may be 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC).

Suitably, the second lipid may form the external lipid bilayer of the liposome.

Suitably, a nanodomain of the first lipid may be encapsulated within the external lipid biiayer of the liposome.

Suitably, the liposome may have a diameter of the major axis of the liposome in the range of from about 50 nm to about 250 nm, optionally wherein the liposome has a diameter of the major axis of about 100 nm.

Suitably, the molar ratio of first lipid:second lipid may be between about 1:9 to about 3:1, optionally between about 1:3 to about 1:1, preferably about 1:1.

Suitably, the liposome may further comprise a cargo.

Suitably, the cargo may be an active pharmaceutical ingredient, optionally wherein the active pharmaceutical ingredient is selected from the group consisting of: a small molecule, peptide, protein, inorganic nanoparticle, oligonucleotide, or any combination thereof.

Suitably, the cargo may be an imaging agent, optionally wherein the imaging agent is selected from: MRI contrast agents, PET/SPECT radioactive imaging agents, paramagnetic nanoparticles, fluorescent probes, bioluminescent probes, quantum dots, gold nanoparticles, optical coherence tomography agents, fluorescent proteins, fluorescent/radioactive latex beads/polymers, photoacoustic imaging agents (eg carbon nanotubes), Raman spectroscopy agents, nanobubbles, or any combination thereof.

In another aspect, the invention provides a composition comprising a liposome as defined herein.

In another aspect, the invention provides a pharmaceutical composition comprising a liposome as defined herein and a pharmaceutically acceptable excipient, adjuvant, diluent and/or carrier.

Suitably, the composition may further comprise at least one of: a preservative, an antioxidant, a buffering agent, an anionic polymer, or any combination thereof.

In another aspect, the invention provides a liposome as defined herein, or a composition comprising a liposome as defined herein, for use in therapy, diagnostics and/or theranostics.

In another aspect, the invention provides a liposome as defined herein, or a composition comprising a liposome as defined herein, for use in treating a brain disease in a subject in need thereof.

Suitably, the brain disease may be selected from: Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, brain cancer, brain tumour, amyotrophic lateral sclerosis (ALS), essential tremor, huntington’s disease, Machado-Joseph disease, glaucoma, hereditary optic neuropathy (Leber), retinitis pigmentosa, meningitis, viral meningitis, inflammatory brain disease, psychotic disorder, narcolepsy, epilepsy/ seizure, and cranial nerve disorder.

Suitably, the subject may have been pre-treated with dextran sulphate.

Suitably, the liposome or composition may be for separate, simultaneous or sequential administration with dextran sulphate to the subject.

In another aspect, the invention provides a method of treating a disease, wherein the method comprises administering a therapeutically effective amount of a liposome as defined herein, or a composition comprising a liposome as defined in herein, to a subject in need thereof.

Suitably, the disease may be a brain disease.

Suitably, the method may comprise pre-treating the subject with dextran sulphate prior to administering the liposome or composition.

Suitably, the method may comprise separate, simultaneous or sequential administration of the liposome or composition and dextran sulphate to the subject.

In another aspect, the invention provides for the use of a liposome as defined herein, or a composition comprising a liposome as defined herein, for the manufacture of a medicament for the treatment of a disease in a subject in need thereof.

Suitably, the disease may be a brain disease.

Suitably, the subject may have been pre-treated with dextran sulphate.

In another aspect, the invention provides a method for delivering a cargo to the blood brain barrier of a subject comprising administering a liposome as defined herein, or a composition comprising a liposome as defined herein, to the subject.

Suitably, the subject may have been pre-treated with dextran sulphate.

In another aspect, the invention provides for the 3use of a liposome as defined herein, or a composition comprising a liposome as defined herein, for delivering a cargo to the blood brain barrier of a subject.

Suitably, the subject may have been pre-treated with dextran sulphate.

In another aspect, the invention provides an in vitro use of a liposome as defined herein, or a composition comprising a liposome as defined herein, for delivering a cargo to an endothelial cell.

In another aspect, the invention provides a method of making a liposome as defined herein comprising the steps of: i) selecting a first lipid of Formula I:

wherein R1 and R2 are each independently selected from H, Cio-C3o-alkyl, Cw-C3o-alkenyl, Cw-C3o-alkynyl, C(0)-Cio-C3o-alkyl, C(0)-Cio-C3o-alkenyl and C(0)-Cio-C3o-alkynyl; R3 is independently selected from H, Cw-C3o-alkyl, Cw-C3o-alkenyl and Cw-C3o-alkynyl; wherein a single one of R1, R2 and R3 is H; X1 and X2 are each independently selected from -0-, -S- and -NR4-; X3 is independently selected from a bond, -0-, -S-, -NR4-, -C(0)-, -C(0)0-, -0C(0)-, -C(0)-NR4-, -NR4C(O)- and -0P(0)20-; wherein if R3 is Η, X3 is not a bond; R4 is independently selected from H and C-i-C-t-alkyl;

Each n is an integer independently selected from 1 to 4, preferably 1 or 2; or a pharmaceutically acceptable salt thereof; ii) selecting a second lipid which combines with the first lipid to make a liposome, wherein phase separation occurs between the first lipid and the second lipid in the liposome; and iii) combining the first lipid and the second lipid, and optionally a cargo, to make the liposome as defined herein.

In another aspect, the invention provides a kit for preparing a liposome as defined herein, the kit comprising: a) a first lipid of Formula I:

wherein R1 and R2 are each independently selected from H, Cio-C3o-alkyl, Cw-C3o-alkenyl, Cio-C3o-alkynyl, C(0)-Cw-C3o-alkyl, C(0)-Cw-C3o-alkenyl and C(0)-Cw-C3o-alkynyl; R3 is independently selected from H, Cw-C3o-alkyl, Cio-C3o-alkenyl and Cio-C3o-alkynyl; wherein a single one of R1, R2 and R3 is H; X1 and X2 are each independently selected from -0-, -S- and -NR4-; X3 is independently selected from a bond, -0-, -S-, -NR4-, -C(0)-, -C(0)0-, -0C(0)-, -C(0)-NR4-, -NR4C(O)- and -0P(0)20-; wherein if R3 is Η, X3 is not a bond;

R4 is independently selected from H and Ci-C4-alkyl; each n is an integer independently selected from 1 to 4, preferably 1 or 2; or a pharmaceutically acceptable salt thereof; and, b) a second lipid, wherein the first lipid and second lipid are capable of phase separation when mixed to form a liposome.

Suitably, the lipid of formula I may be a lipid of formula II:

wherein X3 is -NHC(O)- or -OC(O)-; wherein R1 and R2 are each independently selected from H, C(O)-Cw-C30-alkenyl and 0(0)-Cio-C3o-alkynyl; R3 is independently selected from H, Cw-C3o-alkenyl and Cio-C3o-alkynyl; wherein a single one of R1, R2 and R3 is H.

Suitably, the first lipid may be:

wherein R5 and R8 are each independently selected from C(0)-Cw-C3o-alkyl, C(0)-Cw-C3o-alkenyl and 0(0)-0 io-C3o-alkynyl; and R7 is independently at each occurrence Ci-C4-alkyl.

Suitably, the phospholipid may be selected from any one of phosphatidylcholine (PC), phos-phatidylglycerol (PG), phosphatidylserine (PS), phosphatidylethanolamine (PE), phosphati-dylglyceride, phosphatidic acid (PA), phospholsphingolipid, or any combination thereof.

Suitably, the phospholipid may be a phosphatidylcholine (PC).

Suitably, the phosphatidylcholine (PC) may be selected from the group consisting of 1,2-didecanoyl-sn-glycero-3-phosphocholine (DDPC), 1,2-dierucoyl-sn-glycero-3-phosphocho-line (DEPC), 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLOPC), 1,2-dilauroyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-dis-tearoyl-sn-glycero-3-phosphocholine (DSPC), 1-myristoyl-2-palmitoyl-sn-glycero-3-phospho-choline (MPPC), 1-myristoyl-2-stearoyl-sn-glycero-3-phosphocholine (MSPC), 1-palmitoyl-2-myristoyl-sn-3-phosphocholine (PMPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1-palmitoyl-2-stearoyl-sn-glycero-3-phosphocholine (PSPC), 1-stearoyl-2-myristoyl-sn-glycero-3-phosphocholine (SMPC), 1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine (SOPC), 1-stearoyl-2-palmitoyl-sn-glycero-3-phosphocholine (SPPC), egg phosphatidylcholine (EPC), soy PC, hydro soy PC (HSPC), brain PC, heart PC, liver PC, or any combination thereof.

Throughout the description and claims of this specification, the words “comprise” and “contain” and variations of them mean “including but not limited to”, and they are not intended to (and do not) exclude other moieties, additives, components, integers or steps.

Throughout the description and claims of this specification, the singular encompasses the plural unless the context otherwise requires. In particular, where the indefinite article is used, the specification is to be understood as contemplating plurality as well as singularity, unless the context requires otherwise.

Features, integers, characteristics, compounds, chemical moieties or groups described in conjunction with a particular aspect, embodiment or example of the invention are to be understood to be applicable to any other aspect, embodiment or example described herein unless incompatible therewith.

The patent, scientific and technical literature referred to herein establish knowledge that was available to those skilled in the art at the time of filing. The entire disclosures of the issued patents, published and pending patent applications, and other publications that are cited herein are hereby incorporated by reference to the same extent as if each was specifically and individually indicated to be incorporated by reference. In the case of any inconsistencies, the present disclosure will prevail.

Various aspects of the invention are described in further detail below.

BRIEF DESCRIPTION OF THE DRAWINGS

Figure 1A shows a workflow for screening BBB-targeting liposomes in embryonic zebrafish. 1B shows transgenic (kdrkGFP) zebrafish embryo at 3 days post-fertilisation (dpf) coexpressing GFP in all endothelial cells. 1c shows a dorsal view of the brain endothelium (kdrkGFP) at 3dpf. 1d shows a schematic of the BBB vasculature of embryonic zebrafish at 3dpf (see also: Xie, J.; Farage, E.; Sugimoto, M.; Anand-Apte, B. ‘A novel transgenic zebrafish model for blood-brain and blood-retinal barrier development’ BMC Dev. Biol. 2010, 1-14). Red vessels depict claudin-5+ endothelial cells as a marker for the BBB. Black arrow/vessels indicate differentiation into systemic endothelial cells. 1e shows BBB-targeting liposomes (+ 1mol% DOPE-LR) accumulating at the BBB of embryonic zebrafish at 3dpf. White arrow indicates point of endothelial cell differentiation. 1f shows control liposomes (100% DSPC) - showing no targeting of the BBB. 1g shows lipid components of BBB-targeting liposomes - optimally in a 1:1 molar ratio.

Figure 2 shows ApoE-targeted liposomes targeting the liver and kidney - where LDL receptors are highly expressed (Top panels). Transferrin receptor targeted liposomes targeting immature red blood cells (RBCs) - where transferrin receptor is highly expressed (Bottom panels).

Figure 3 shows the two regioisomers of PAPAP3 synthesised and a 1H-NMR spectrum of PAPAP3.

Figure 4 shows transmission electron microscopy images demonstrating that DSPC:PAPAP3 liposomes can be formulated to encapsulate gold nanoparticles.

Figure 5 shows the results of different PAPAPs formulated 1:1 with DSPC. DSPC:PAPAP1 did not target the BBB in zebrafish (top left panel). DSPC:PAPAP3 targeted the BBB in zebrafish (top right panel). DSPC:PAPAP4 showed some binding to the BBB (middle left panel). DSPC:PAPAP5 demonstrated strong off-targeting to venous endothelial cells (middle right panel). DSPC:PAPAP6 and DSPC:PAPAP7 shows low binding to the BBB (bottom panels).

Figure 6 shows the molecular structures of several first lipids used in the invention.

Figure 7 shows that DSPC:PAPAP3 liposomes formulated in a 3:1 molar ratio accumulate at the BBB.

Figure 8 shows that DSPC:PAPAP3 liposomes formulated in a 9:1 molar ratio also accumulate at the BBB.

Figure 9 shows that DSPG:PAPAP3 liposomes formulated in a 1:1 molar ratio exhibit low level binding at the BBB and mild off-target interaction with veins (white arrow).

Figure 10 shows that DOPS:PAPAP3 liposomes formulated in a 1:1 molar ratio exhibit no significant binding at the BBB and strong off-target interaction with veins (white arrow).

Figure 11 shows that DPPC:PAPAP3 liposomes formulated in a 1:1 molar ratio exhibit binding at the BBB however is potently taken up by plasma exposed macrophages (large white spots).

Figure 12 shows that DMPC:PAPAP3 liposomes formulated in a 1:1 molar ratio exhibit low level binding at the BBB and some uptake by plasma exposed macrophages (mostly freely circulating).

Figure 13 shows that that DOPC:PAPAP3 liposomes formulated in a 1:1 molar ratio exhibit no significant binding at the BBB and strong off-target interactions with the veins (white arrow).

Figure 14 shows that DSPC:PAPAP3 liposomes formulated in a 1:1 molar ratio exhibit very significant binding at the BBB (left hand (dark) arrow) but with significant off-targeting to the veins (right hand (white) arrow).

Figure 15 shows cyoEM images of the liposomes of the invention (DSPC:PAPAP3 liposomes formulated in a 1:1 molar ratio) and a schematic drawing of liposomes according to the invention.

DETAILED DESCRIPTION

As used herein, a “liposome” is a colloidal particle that is prepared from polar lipid molecules derived either from natural sources or chemical synthesis. The lipids form an spherical/oval, closed structure, wherein an external curved lipid bilayer forms around an aqueous core.

The liposome may include one or several lipid bilayers enclosing the aqueous core (e.g. see Figure 15). A liposome typically serves as a carrier of an entity (i.e. a cargo) such as, without limitation, a chemical compound, a combination of compounds, a supramolecular complex of a synthetic or natural origin, a genetic material, a living organism, a portion thereof, or a derivative thereof, that is capable of having a useful property or exerting a useful activity.

The liposomes described herein comprise two different lipids, described herein as a “first lipid” and a “second lipid”. The lipids may be of a natural and/or a synthetic/semi-synthetic origin. Mixtures of natural and synthetic/semi-synthetic lipids may also be employed.

The liposomes described include a first lipid of Formula I:

wherein R1 and R2 are each independently selected from H, Cw-C3o-alkyl, Cw-C3o-alkenyl, Cw-C3o-alkynyl, C(0)-Cio-C3o-alkyl, C(0)-Cio-C3o-alkenyl and C(0)-Cio-C3o-alkynyl; R3 is independently selected from H, Cw-C3o-alkyl, Cio-C3o-alkenyl and Cw-C3o-alkynyl; wherein a single one of R1, R2 and R3 is H; X1 and X2 are each independently selected from -0-, -S- and -NR4-; X3 is independently selected from a bond, -0-, -S-, -NR4-, -0(0)-, -0(0)0-, -00(0)-, -0(0)-NR4-, -NR4C(O)- and -0P(0)20-; wherein if R3 is Η, X3 is not a bond; R4 is independently selected from H and Ci-C4-alkyl; each n is an integer independently selected from 1 to 4, preferably 1 or 2; or a pharmaceutically acceptable salt thereof.

In one embodiment, the lipid of formula I is a lipid of formula II:

wherein X3 is -NHC(O)- or -00(0)-;

wherein R1 and R2 are each independently selected from H, C(0)-Cw-C3o-alkenyl and C(O)-Cio-C3o-alkynyl; R3 is independently selected from H, Cw-C3o-alkenyl and Cio-C3o-alkynyl; wherein a single one of R1, R2 and R3 is H.

The following statements apply, where not mutually exclusive, to both the lipids of formula I and the lipids of formula II.

It may be that R1 and R2 are each independently selected from H, C(0)-Cw-C3o-alkyl, C(O)-Cw-C3o-alkenyl and C(0)-Cw-C3o-alkynyl. It may be that R1 and R2 are each independently selected from H and C(0)-Cw-C3o-alkenyl.

It may be that R3 is independently selected from H and Cio-C3o-alkenyl.

It may be that R1 and R2 are each independently selected from H, Cio-C3o-alkenyl and C(O)-Cw-C3o-alkenyl; and that R3 is independently selected from H and Cio-C3o-alkenyl and C10-C3o-alkynyl.

It may be that R1 and R2 are each independently selected from H and C(0)-Cio-C3o-alkenyl; and that R3 is independently selected from H and Cio-C3o-alkenyl.

It may be that a single one of R1 and R2 is H.

It may be that R1 is H. It may be that R2 is H.

It may be that R1, R2 and R3 are selected such that any alkyl, alkenyl or alkynyl group in R1, R2 and R3 is from 12 to 25 carbons atoms in length. It may be that R1, R2 and R3 are selected such that any alkyl, alkenyl or alkynyl group is from 15 to 20 carbons atoms in length.

Where R1, R2 and/or R3 are alkenyl it may be that that alkenyl group comprises more than one carbon-carbon double bond. Alternatively, it may be that the alkenyl group comprises a single carbon-carbon double bond. Where an alkenyl group comprises more than one carbon-carbon double bond it may be that at least two sp3 carbons separate any two carbon-carbon double bonds.

Where R1, R2 and/or R3 are alkenyl comprising a single carbon-carbon double bond, the carbon atom at one end of the double bond is situated x carbons away from X1, X2 and X3 and the carbon atom at the other end of the double bond is y carbons away from the end of the alkenyl group, x and y are selected dependent on the length of the alkenyl group and may each be an integer selected from 0 to 28, the sum of x and y being an integer from 8 to 28 where the alkenyl is a Cw-C-jo-alkenyl. It may be that x is not less than 2. It may be that y is not less than 2. It may be that x is not less than 5. It may be that y is not less than 5. It may be that neither It may be that y+3>x>y-3. It may be that y+2>x>y-2. It may be that y+1>x>y-1.

It may be that X1 and X2 are both -O-. X3 may be independently selected from -0-, -S-, -NR4-, -C(0)-, -0(0)0-, -00(0)-, -0(0)-NR4-, -NR4C(O)- and -0P(0)20-.

It may be that X3 is selected from -00(0)- and -NR4C(O)-, e.g. -NHC(O)-. It may be that X3 is -NR4C(O)-, e.g. -NHC(O)-.

The term Ca-Cb refers to a group with a to b carbon atoms.

The term “alkyl” refers to a linear saturated hydrocarbon chain.

The term “alkenyl” refers to a linear hydrocarbon chain containing at least one carbon-carbon double bond. The double bond(s) may be present as the E or Z isomer.

The term “alkynyl” refers to a linear hydrocarbon chain containing at least one carbon-carbon triple bond.

The first lipid may be:

or a pharmaceutically acceptable salt thereof.

The term “regioisomer” may mean, for example, that a double bond is in a different position along an alkyl chain. It may also mean that an acyl group is attached to an alternative heteroatom.

Many lipids of formula I comprise a chiral centre. Where the lipid of formula I comprises a chiral centre, the lipid may be in the form of the (R)-enantiomer or the (S)-enantiomer or a mixture thereof. Where the lipid is a mixture, it may be that the (R)-enantiomer predominates or that the (S)-enantiomer predominates or it may a racemic mixture of the (R)-enantiomer or the (S)-enantiomer.

The liposome may comprise a mixture of more than one lipid of formula I. In particular, the liposome may comprise a mixture of two regioisomers which differ in that in the first regioisomer R1 is H and in the second regioisomer R2 is H. For the absence of doubt, in this case the R2 group in the first isomer is the same as the R1 group in the second isomer.

As used herein, the “first lipid” is also referred to as “Lipid 1” or “PAPAP”.

In addition to the first lipid described above, the liposomes described herein also comprise a second lipid (also described herein as the “co-formulant” lipid).

The first and second lipids undergo phase separation when mixed to form a liposome.

As used herein, “phase separation” means that the two lipids within the liposome are present in two separate phases after mixing to form a liposome. It will also be understood that whilst the two lipids are in two separate phases, there is still interaction between the phases such that the first lipid may be protected by the second lipid from an aqueous environment. The aqueous environment may, for example, either be the aqueous core of the liposome or an external aqueous environment. An example of the phase separation is shown in Figure 15.

Phase separation is caused by differences in packing parameters within lipid bilayers.

Phase separation usually refers to the formation of lipid rafts/domains (for example cholesterol rich domains), wherein the lipid raft/domain is enriched in a particular lipid (or subset of lipids) compared to other regions of the lipid bilayer. In the context of the invention, the phrase “phase separation” is used to describe lipid droplet formation (also described as nanodomain formation herein) as shown in Figure 15, wherein a lipid droplet (or nanodomain) of the first lipid is illustrated. For the avoidance of doubt, a simple test can be performed to determine whether phase separation (i.e. first lipid droplet formation) as defined herein occurs between two lipids in a liposome. The test is as follows: Mix individual lipids (lipid 1 and 2), stored as stock solutions (1-1 OmM) in chloroform, to the desired molar ratios in a glass vial and dry to a film, first under a stream of N2 then >1h under vacuum. Hydrate the lipid film with ddH2O to a total lipid concentration of 5mM (solution may require heating to 80°C and/or gentle vortexing. do not sonicate). Generate liposomes through extrusion above the Tm of all lipids (>65°C, Mini-extruder with heating block, Avanti Polar Lipids, Alabaster, US) by passing hydrated lipid solutions 11 times through 2 x 400 nm polycarbonate (PC) membranes (Nucleopore Track-Etch membranes, Whatman), followed by 11 times through 2 x 100 nm PC pores. All liposomes were stored at 4°C. Check liposome size and polydispersity by DLS - optimal liposomes should be 100-150nm in size (hydrodynamic diameter) and have a polydispersity of > 0.2.To check for the presence of lipid droplets perform cryoEM imaging on this sample as described in the examples section below). The majority of liposomes should appear as round or elipse structures (ranging from 50-250nm longest axis) with a clearly defined outer membrane (dark contrast, approx. 5 nm in width) and a lipid droplet (dark contrast, approx. 10-50nm in diameter) clearly visible and resembling a protrusion from the lipid bilayer (see Figure 15).

Accordingly, a person of skill in the art can readily identify appropriate lipids for formation of the liposomes described herein, wherein phase separation occurs between the lipids in the liposome using the specific test set out above.

In one embodiment, the second lipid has the following formula III:

wherein

R5 and R6 are each independently selected from C(0)-Cw-C3o-alkyl, C(0)-Cw-C3o-alkenyl and C(O)-C w-C3o-alkynyl; and R7 is independently at each occurrence Ci-C4-alkyl.

The second lipid may be a phospholipid. The term “phospholipid” refers to a lipid which has a hydrophilic portion comprising a phosphate group, and particularly includes lipids based on phosphatidylcholine (PC), phosphatidylglycerol (PG), phosphatidylserine (PS), phosphatidylethanolamine (PE), phosphatidylglycerides (e.g. phosphoinositide (PI)), phosphatidic acid (PA), phospholsphingolipids (e.g. sphingomyelin), or any combination thereof.

The phospholipid is preferably of natural origin. Natural phospholipids are preferably membrane lipids derived from various sources of both vegetable (e.g. rapeseed, sunflower, etc., or, preferably, soybean) and animal origin (e.g. egg yolk, bovine milk, etc.). Phospholipids from soybean, a major source of vegetable phospholipids, are normally obtained from the by-products (i.e. lecithins) in the refining of crude soybean oil by the degumming process. The lecithins are further processed and purified using other physical unit operations, such as fractionation and/or chromatography. Other phospholipids may be obtained, for example, by pressing various suitable seeds and grains, followed by solvent extraction and then further processing as described above. Phospholipids derived from a natural source (e.g. egg phosphatidylcholine (EPC), soy PC, hydro soy PC (HSPC), brain PC, heart PC, liver PC etc) may not be completely pure (i.e. may comprise some impurities). Phospholipids that are useful in forming the liposomes described herein may also be obtained from e.g. Avanti Polar Lipids, Lipoid GmbH, or Sigma-Aldrich.

The phospholipid of choice may be a phosphatidylcholine (PC). For example, the phosphatidylcholine (PC) may be selected from the group consisting of 1,2-didecanoyl-sn-glycero-3-phosphocholine (DDPC), 1,2-dierucoyl-sn-glycero-3-phosphocholine (DEPC), 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLOPC), 1,2-dilauroyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1-myristoyl-2-palmitoyl-sn-glycero-3-phosphocholine (MPPC), 1-myristoyl-2-stearoyl-sn-glycero-3-phosphocholine (MSPC), 1-palmitoyl-2-myristoyl-sn-3-phosphocholine (PMPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1-palmitoyl-2-stearoyl-sn-glycero-3-phosphocholine (PSPC), 1-stearoyl-2-myristoyl- sn-glycero-3-phosphocholine (SMPC), 1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine (SOPC), 1-stearoyl-2-palmitoyl-sn-glycero-3-phosphocholine (SPPC), egg phosphatidylcholine (EPC), soy PC, hydro soy PC (HSPC), brain PC, heart PC, liver PC or any combination thereof.

The phospholipid may be 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC).

The molar ratio of first lipid:second lipid in the liposome may be between about 1:9 to about 3:1. In other words, the molar ratio may be about 1:9, 1:8, 1:7, 1:6, 1:5, 1:4, 1:3, 1:2, 1:1, 1.5:1,2:1, 2.5:1, 3:1, or any range there inbetween. In one example, the molar ratio of first lipid:second lipid in the liposome may be between about 1:3 to about 1:1, and is preferably about 1:1 (wherein about 1:1 encompasses 0.5:1.4 to 1.4:0.5).

It will be clear that because phase separation occurs between the first lipid and the second lipid in the liposome, the external lipid bilayer of the liposome will predominantly be formed by either one (but not both) of the lipids. As the second lipid is typically more amphiphilic in character than the first lipid, the second lipid typically forms the external lipid bilayer of the liposome. In other words, the second lipid may be the predominant lipid in the lipid bilayer that forms the liposome outer boundary, and interacts with the external environment. This does not exclude the first lipid being present in the external lipid bilayer, as described in more detail below.

Phase separation of the first lipid and the second lipid in the liposome results in a nanodomain (also described as a lipid droplet) of the first lipid forming in the liposome. A “nanodomain of the first lipid” refers to a lipid component of the liposome that is enriched with the first lipid (i.e. is predominantly made up of the first lipid). In other words, the first lipid may form a lipid droplet in the liposome, wherein the lipid droplet is enriched in (i.e. predominantly made up of) the first lipid. The nanodomain may comprise at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, at least 95%, at least 99% of the total amount of the first lipid in the liposome. The nanodomain may therefore be formed substantially of the first lipid. Suitably, the nanodomain does not include an aqueous core.

Suitably, the nanodomain or lipid droplet of the invention may have a diameter of a major axis in the range of about 10 to about 100 nm (e.g. about 10, 15, 20, 25, 30, 35, 40, 45, 50, 60, 70, 80, 90 or 100 nm, or any range there inbetween). In other words, the range may from any one of the specifically cited diameters as a starting point, to any one of the specifically cited diameters as an end point of the range.

The nanodomain (or lipid droplet) of the first lipid may become encapsulated (or embedded) within the external lipid bilayer of the liposome.

In this context, encapsulated within the external lipid biiayer means that the nanodomain may be located between the two lipid monolayers of the external lipid biiayer (see Figure 15). In other words, the nanodomain or lipid droplet of the first lipid may form such that it is sandwiched between the two monolayers of the external lipid biiayer of the liposome. Typically, the external lipid biiayer is predominantly made up of the second lipid. Therefore, in this context, a layer of second lipids (e.g. a monolayer of second lipids) may act as a barrier between the nanodomain and the external environment outside the liposome. In this example, the second lipid may also form a barrier between the nanodomain of the first lipid and the aqueous core of the liposome.

As discussed above, the nanodomain (or lipid droplet) of the first lipid may also become embedded within the external lipid biiayer of the liposome. In this context, embedded within the external lipid biiayer means that the nanodomain (or lipid droplet) is predominantly (but not completely) surrounded by the two lipid monolayers of the external lipid biiayer. In other words, a proportion of the nanodomain or lipid droplet of the first lipid may protrude from the external lipid biiayer of the liposome (e.g. into the aqueous core of the liposome, or into the external environment outside the liposome) or form part of the external lipid biiayer, and thus be in direct contact with the aqueous core or external environment. In this context, the proportion of nanodomain or lipid droplet that may be in direct contact with the external environment or aqueous core may be less than 40%, less than 30%, less than 20%, less than 10%, less than 5% of the total amount of the first lipid in the nanodomain or lipid droplet.

The nanodomain or lipid droplet of the first lipid may also be encapsulated or embedded within two lipid bilayers formed by the second lipid e.g. the external biiayer and a second biiayer within the liposome that acts as a barrier between the nanodomain and the aqueous core of the liposome. Reference to lipid “monolayer” herein can therefore be replaced with reference to lipid “biiayer” herein (see also Figure 15).

The liposome may take any shape, although the liposomes described herein are usually approximately ellipsoid.

The liposome described herein will typically have a diameter of a major axis of the liposome about 50 nm or above so that, once administered to a subject, the liposome is not filtered out of the bloodstream by the kidneys. However, the liposome described herein will typically also have a diameter of the major axis about 250 nm or below so that once administered to a subject the rate of degradation by the liver is minimised. Therefore, the liposome defined herein may have a diameter of the major axis of between about 50 nm and about 250 nm for example between about 75 nm and about 200 nm, between about 90 nm and 150 mm, or about 100 nm.

The liposome may have a diameter of a major axis of about 100 nm. The liposome may have a diameter of a major axis of about 50 nm to about 150 nm, or about 80 nm to about 140 nm, or about 70 nm to about 130 nm, or about 75 to nm to about 125 nm, or about 75 nm to about 100 nm, for example, about 100 nm. The liposome may therefore have a diameter of a major axis of about 50 nm, above 50 nm, about 55 nm, about 60 nm, about 65 nm, about 70 nm, about 75 nm, about 80 nm, about 85 nm, about 90 nm, about 95 nm, about 100 nm, about 105 nm, about 110 nm, about 115 nm, about 120 nm, about 125 nm, about 130 nm, about 135 nm, about 140 nm, about 145 nm, about 150 nm.

Stated another way, the liposome may have a diameter of the major axis defined by a size range, with the lower end of the size range being any size selected from about 50 nm, 51 nm, 52 nm, 53 nm, 54 nm, 55 nm, 56 nm, 57 nm, 53 nm, 59 nm, 60 nm, 61 nm, 62 nm,63 nm, 64 nm, 65 nm, 66 nm, 67 nm, 68 nm, 69 nm, 70 nm, 71 nm, 72 nm,73 nm,74 nm, 75 nm, 76 nm, 77 nm, 78 nm, 79 nm, 80 nm; and with the upper end of the size range being any size selected from about 175 nm, 170 nm, 165 nm, 160 nm, 155 nm, 150 nm, 145 nm, 144 nm, 143 nm, 142 nm, 141 nm, 140 nm, 139 nm, 138 nm, 137 nm, 136 nm, 135 nm, 134 nm, 133 nm, 132 nm, 131 nm, 130 nm, 129 nm, 128 nm, 127 nm, 126 nm, 125 nm, 124 nm, 123 nm, 122 nm, 121 nm, 120 nm, 119 nm, 118 nm, 117 nm, 116 nm, 115 nm, 114 nm, 113 nm, 112 nm, 111 nm, 110 nm, 109 nm, 108 nm, 107 nm, 106 nm, 105 nm, 104 nm, 103 nm, 102 nm, 101 nm, 100 nm, 99 nm, 98 nm, 97 nm, 98 nm, 95 nm, 94 nm, 93 nm, 92 nm, 91 nm, or 90 nm.

As used herein, reference to the “diameter of the major axis” refers to the largest dimension of the liposome.

Accordingly, the compositions may contain liposomes that are a range of different sizes.

Size of liposomes may be affected by a number of factors, such as, for example, lipid composition and method of preparation, and can be determined by a number of techniques. Reference to a diameter of the major axis of a liposome as used herein may also refer to a mean diameter of the major axis of the liposomes within said composition.

The size of a liposome may also be determined by DLS which is typically reported as the ‘Z-average size’ and is the mean particle size. Such measurements are often accompanied by the size distribution or polydispersity index (PDI) of the sample, in which 0 = perfectly uniform, 1 = complete size heterogeneity. Nanoparticle systems having a PDI of from 0 to 0.1 are considered to be ‘tightly uniform’, those having a PDI of from 0.1 to 0.4 are ‘moderately polydisperse’; and those having a PDI of >0.4 are ‘highly polydisperse’. It is generally accepted <0.2 PDI is required to describe a homogenous nanoparticle population. Sizes may be determined according to techniques that are known to the person skilled in the art, including electron microscopy techniques (such as transmission electron microscopy (TEM) and cryoTEM) and light scattering techniques (such as laser diffraction and dynamic light scattering). Laser diffraction or dynamic light scattering (as is described elsewhere herein) may be used to determine the size (and size distribution) of the liposomes.

CryoTEM techniques are generally preferred over TEM as the sample does not need to be dried; this is particularly advantageous for liposomes because these particles can be kept in their native state. These techniques allow direct visualisation of liposomes and are often used as a qualitative tool to visualise liposome size and morphology. Quantification of size and polydispersity is possible if a sufficient number of particles are individually analysed.

The liposomes described herein may contain a plurality of different lipids, provided they contain a first lipid and a second lipid as described above, and phase separation occurs between the first lipid and the second lipid in the liposome. The liposome typically also fulfils the size requirements described above. Additional lipids that may be present in the liposomes include those described above as well as others that are known to be useful in forming liposomes for clinical use. For example, the liposomes may contain one, two, three or more different lipids. It is preferred that the liposomes are formed from predominantly only a first lipid and a second lipid. That is, it is preferred that substantially all of the lipid molecules in the liposomes are either a first lipid or a second lipid as described herein. At least 70% (e.g. at least 90%, e.g. at least 95%, e.g. at least 99%, e.g. 100%) by weight of the lipid molecules in the liposomes may be either a first lipid or a second lipid as described herein.

The liposomes described herein may further comprise a cargo. The cargo may be any entity such as, without limitation, a chemical compound, a combination of compounds, a supramolecular complex of a synthetic or natural origin, a genetic material, a living organism, a portion thereof, or a derivative thereof, that is capable of having a useful property or exerting a useful activity. The cargo may be hydrophilic or hydrophobic.

The skilled person will appreciate that any active pharmaceutical ingredient or any imaging agent may be used in the context of the invention. Non-limiting examples are provided below. For the avoidance of doubt, a liposome may contain a plurality of cargoes e.g. two or more active pharmaceutical ingredients, two or more imaging agents, or a mixture of active pharmaceutical ingredients and imaging agents.

In one example, the cargo is an active pharmaceutical ingredient such as a small molecule, peptide, protein, inorganic nanoparticle, oligonucleotide (or any combination thereof). Where compatible, terms “active pharmaceutical ingredient” and “drug” are used interchangeably herein.

Alternatively, the cargo may be an imaging agent, which includes MRI contrast agents (e.g. Gd), PET/SPECT radioactive imaging agents (e.g. 111ln, 64Cu), paramagnetic nanoparticles (e.g. iron oxide), fluorescent probes, bioluminescent probes, quantum dots, gold nanoparticles, optical coherence tomography agents (e.g. gold nanorods, fluorescent proteins, fluorescent/radioactive latex beads/polymers, photoacoustic imaging agents (eg carbon nanotubes), Raman spectroscopy agents (e.g, AuNPs), nanobubbles (or any combination thereof).

It is advantageous to use imaging agents which are suitable for radioimaging. This is because the liposomes have been found to target the BBB and information about the localisation of these liposomes may be useful to a clinician. Radioimaging techniques that may be mentioned include PET, SPECT and MRI, and imaging agents used in these methods would be known to the skilled person. A cargo (e.g. an imaging agent) may be bound to (or adsorbed onto, or tethered to) the outer surface of the liposome. This would be advantageous if, for example, they are being used in diagnostic methods.

Alternatively, a cargo may be incorporated into the liposome. For example, the cargo may be may be encapsulated within and/or covalently bound to said liposomes.

The cargo may be encapsulated by at least one lipid biiayer of the liposome such that it is located within the aqueous core. Alternatively, the cargo may be located within or associated with the lipid biiayer of the liposome via covalent bonding, electrostatic or hydrophobic interactions.

Drugs can be encapsulated in the micellar core by chemical conjugation (e.g. by forming a covalent bond between the drug and the hydrophobic core of the micelle) or by physical entrapment through dialysis or emulsification. Z. Ahmad et al. RSC Adv., 2014,4,17028 describes a number of polymeric micelle systems as delivery vehicles, methods of making them and methods of loading the micelles with drugs.

References herein to “encapsulation” (or similar) of one or more ingredients within the liposome includes references to liposomes in which some or all of the active pharmaceutical ingredients and imaging agents are covalently bound to said liposome. It is to be expected that while a substantial proportion of that active pharmaceutical ingredient or imaging agent will be encapsulated within the liposome, a proportion may not be encapsulated therein. By reference to substances being contained “within” liposomes, we include that substances may be wholly encapsulated within the liposome structure (e.g. within the lipid bilayer wall(s), or within a region that is enclosed within that lipid bilayer wall(s)). Alternatively, the substance may be covalently bound to one or more constituents of the liposome particle, e.g. the lipid bilayer structure in the case of liposomes. Substances that are covalently bound in this way may become incorporated into the endothelial cells at the BBB as a result of the receptor-mediated endocytic process by which the liposomes themselves become taken into those cells.

It is preferred that at least a significant proportion (e.g. at least 75% by weight) of the active pharmaceutical ingredient or imaging agent is encapsulated within (or covalently bound to) the liposomes.

The liposomes may be prepared to contain the desired cargo in a liposome- incorporated form. The process of incorporation of a desired cargo into a liposome is often referred to as "loading". The liposome-incorporated cargo may be completely or partially located in the interior space of the liposome, within the bilayer membrane of the liposome, or associated with the exterior surface of the liposome membrane. The incorporation of cargo into liposomes is also referred to as encapsulation or entrapment, and these three terms are used herein interchangeably with the same meaning.

The intent of the liposomal encapsulation of cargo is often to protect the cargo from the destructive environment while providing a opportunity for the encapsulated cargo to exert its activity mostly at the site or in the environment where such activity is advantageous but less so in other sites where such activity may be useless or undesirable.

This phenomenon is referred to as delivery. For example, a drug substance within the liposome can be protected from the destruction by enzymes in the body, but become released from the liposome and provide treatment at the site of disease.

Ideally, such liposomes can be prepared to include the desired cargo (i) with high loading efficiency, that is, high percent of encapsulated cargo relative to the amount taken into the encapsulation process; (ii) high amount of encapsulated cargo per unit of liposome bilayer material; (iii) at a high concentration of encapsulated cargo, and (iv) in a stable form, i.e., with little release (leakage) of an encapsulated cargo upon storage or generally before the liposome appears at the site or in the environment where the liposome-entrapped cargo is expected to exert its intended activity.

The liposomes described herein may further comprise a coat. The use of liposomes which are coated in order to reduce non-specific cellular interactions is known in the art. A common form of coating involves derivatisation of the liposome with polyethylene glycol (PEG) as a steric shield. See, for example, Immordino M. L, et al., International Journal of

Nanomedicine (2006) 1(3), 297-315. Thus, liposomes that are useful in the methods of the invention may have a coating, e.g. one comprising a plurality of PEG groups. Suitable molecular weights for PEG groups may range from 100 to 5000 PEG units.

The liposomes described herein may form part of a composition i.e. the liposomes may be in a composition with other components. The composition may be a pharmaceutical composition containing the liposomes described herein, which compositions are suitable for use in direct administration to mammals, and especially humans. In this respect, the term “pharmaceutical composition” is intended to encompass compositions that include only components that are regarded in the art as suitable for administration to mammalian, and especially human, patients. Compositions that are suitable for administration to such subjects will be known to the person skilled in the art. In this respect, reference may be made to the Draft Guidance for Industry provided by the U.S. Department of Health and Human Services, Food and Drug Administration (Center for Drug Evaluation and Research (CDER)), entitled “Liposome Drug Products, Chemistry, Manufacturing, and Controls;

Human Pharmacokinetics and Bioavailability; and Labeling” (October 2015). In the context of the present invention, the term may refer to formulations in which drugs are encapsulated within and/or covalently bound to liposomes requiring reconstitution shortly prior to administration in order to avoid leakage of drugs from liposomes into an aqueous carrier. Alternatively, it may mean that the compositions are in the form of a liquid that is ready-to- use, directly from the shelf, and not a formulation in which drugs are encapsulated within and/or covalently bound to liposomes requiring reconstitution prior to administration. A pharmaceutical composition may comprise a liposome described herein along with a pharmaceutically acceptable excipient, adjuvant, diluent and/or carrier.

Compositions may routinely contain pharmaceutically acceptable concentrations of salt, buffering agents, preservatives, compatible carriers, supplementary immune potentiating agents such as adjuvants and cytokines and optionally other therapeutic agents or compounds.

Excipients are natural or synthetic substances formulated alongside a cargo (e.g. an active pharmaceutical ingredient) as described herein, included for the purpose of bulking-up the formulation or to confer a therapeutic enhancement on the active ingredient in the final dosage form, such as facilitating drug absorption or solubility. Excipients can also be useful in the manufacturing process, to aid in the handling of the active substance concerned such as by facilitating powder flowability or non-stick properties, in addition to aiding in vitro stability such as prevention of denaturation over the expected shelf life. Pharmaceutically acceptable excipients are well known in the art. A suitable excipient is therefore easily identifiable by one of ordinary skill in the art. By way of example, suitable pharmaceutically acceptable excipients include water, saline, aqueous dextrose, glycerol, ethanol, and the like.

Adjuvants are pharmacological and/or immunological agents that modify the effect of other agents in a formulation. Pharmaceutically acceptable adjuvants are well known in the art. A suitable adjuvant is therefore easily identifiable by one of ordinary skill in the art.

Diluents are diluting agents. Pharmaceutically acceptable diluents are well known in the art. A suitable diluent is therefore easily identifiable by one of ordinary skill in the art.

Carriers are non-toxic to recipients at the dosages and concentrations employed and are compatible with other ingredients of the formulation. The term “carrier” denotes an organic or inorganic ingredient, natural or synthetic, with which the active ingredient is combined to facilitate the application. The carrier may be chemically inert to the active compounds and may have no detrimental side effects or toxicity under the conditions of use. Pharmaceutically acceptable carriers are well known in the art. A suitable carrier is therefore easily identifiable by one of ordinary skill in the art. By way of example, suitable pharmaceutical carriers may be found in, for example, Remington: The Science and Practice of Pharmacy, 19th ed., Mack Printing Company, Easton, Pennsylvania (1995).

The pharmaceutically acceptable excipient, adjuvant, diluent or may be selected with due regard to the intended route of administration and standard pharmaceutical practice.

The composition may also comprise at least one of: a preservative, an antioxidant, a buffering agent (e.g. dextrose), an anionic polymer (e.g. dextran sulfate or heparin), or any combination thereof.

The compositions may therefore comprise an antioxidant, such as ascorbic acid, butylated hydroxyanisole, butylated hydroxytoluene, citric acid, fumaric acid, malic acid, monothioglycerol, propionic acid, propyl gallate, sodium ascorbate, sodium bisulfite, sodium metabisulfite, potassium metabisulfite, sodium sulfite, tartaric acid or vitamin E. Preferred antioxidants include butylated hydroxytoluene, ascorbic acid and butylated hydroxyanisole. A chelating agent may also be used to reduce the metal ion catalysed oxidation of phospholipid and/or active ingredient(s). Examples of useful chelating agents are ethylenediaminetetraacetic acid (EDTA) and salts thereof (e.g. sodium or potassium EDTA), ethylenediaminetriacetic acid and diethylenetriaminepentaacetic acid (DTPA). It is also possible to use other agents that protect the compositions described herein and, in particular, any unsaturated fatty acid residues that may be present therein, from oxidation. Preferred chelating agents include EDTA and salts thereof.

The compositions described herein can also comprise one or more preservatives. Examples of common preservatives for liquid pharmaceutical compositions are benzalkonium chloride, benzoic acid, butylated hydroxyanisole, butylparaben, chlorbutanol, ethylparaben, methylparaben, propylparaben, phenoxyethanol or phenylethyl alcohol. Preferred preservatives include benzalkonium chloride. Other preservatives that may be mentioned include sorbic acid.

Optional additives, including preservatives, antioxidants, and chelating agents should be selected, in terms of their identity and the amounts employed, keeping in mind that their detrimental effect on liposome stability should be kept at a minimum. For a given agent this can be ascertained by simple experiments, which are well within the understanding of the skilled person. Suitable amounts of such ingredients are however in the range of about 0.01 mg/ml_ to about 10 mg/ml_. It is preferred that the compositions that are useful in the methods of the invention contain at least one preservative, antioxidant, chelating agent, buffering agent and/or viscosity-increasing agent. Suitable amounts of any/all of these optional additives include from about 0.02 to about 5 (e.g. about 3) mg/mL (e.g. from about 0.1 to about 2 mg/mL).

In some embodiments, the (pharmaceutical) composition is sterile and has a purity level of, for example, at least about 90%, at least about 91 %, at least about 92%, at least about 93%, at least about 94%, at least about 95%, at least about 96%, at least about 97%, at least about 98% or at least about 99%.

In some embodiments, the (pharmaceutical) composition comprises a liposome described herein present in the composition in a concentration of about 0.5 mg/mL to about 30 mg/mL (e g., about 1 mg/mL to about 20 mg/mL (e.g., about 1 mg/mL, about 2 mg/mL, about 3 mg/mL, about 4 mg/mL, about 5 mg/mL, about 6 mg/mL, about 7 mg/mL, about 8 mg/mL, about 8 mg/mL, about 10 mg/mL, about 11 mg/mL, about 12 mg/mL, about 13 mg/mL, about 14 mg/mL about 15 mg/mL, about 16 mg/mL, about 17 mg/mL, about 18 mg/mL, about 19 mg/mL, about 20 mg/mL, about 21 mg/mL, about 22 mg/mL, about 23 mg/mL, about 24 mg/mL about 25 mg/mL, about 26 mg/mL, about 27 mg/mL, about 28 mg/mL, about 29 mg/mL, or about 30 mg/mL). in some exemplary embodiments, the concentration of the liposome is about 13 mg/mL, In some embodiments, the liposome is present in the composition in an amount of about 1 mg/mL to about 10 mg/mL, or about 5 mg/mL to about 15 mg/mL, or about 10 mg/mL to about 20 mg/mL, or about 15 mg/mL to about 30 mg/mL. A liposome and/or composition described herein may be used in therapy, or diagnostics such as fortheranostics.

By way of example, the liposomes and/or composition described herein may be used in the treatment of a brain disease in a subject in need thereof.

For the avoidance of doubt, as used herein the term “treatment” includes the therapeutic treatment, as well as the symptomatic treatment, the prophylaxis, or the diagnosis, of a condition. By the term “treat”, “treating”, or “treatment of” (and grammatical variations thereof) it is also meant that the severity of the patient’s condition is reduced, at least partially improved or ameliorated and/or that some alleviation, mitigation or decrease in at least one clinical symptom is achieved and/or there is a delay in the progression of the disease or disorder.

As used here in the term “subject” refers to an individual, e.g., a mammal such as a human, having or at risk of having a specified condition, disorder or symptom. The subject may be a patient i.e. a subject in need of treatment in accordance with the invention. The subject may have received treatment for the condition, disorder or symptom. Alternatively, the subject has not been treated prior to treatment in accordance with the present invention. A person of skill in the art will be fully aware of which types of brain disease may be treated with the liposomes and/or compositions described herein. In a non-limiting example, the brain disease may be selected from: Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, brain cancer, brain tumour, amyotrophic lateral sclerosis (ALS), essential tremor, huntington’s disease, Machado-Joseph disease, glaucoma, hereditary optic neuropathy (Leber), retinitis pigmentosa, meningitis, viral meningitis, inflammatory brain disease, psychotic disorder, narcolepsy, epilepsy/ seizure, and cranial nerve disorder.

Brain and central nervous system (CNS) cancers and tumors that may be targeted include astrocytomas (including cerebellar and cerebral), brain stem glioma, brain tumors, malignant gliomas, ependymoma, glioblastoma, medulloblastoma, supratentorial primitive neuroectodermal tumors, visual pathway and hypothalamic gliomas, primary central nervous system lymphoma, ependymoma, brain stem glioma, visual pathway and hypothalamic glioma, extracranial germ cell tumor, medulloblastoma, myelodysplasia syndromes, oligodendroglioma, myelodysplastic/myeloproliferative diseases, myelogenous leukemia, myeloid leukemia, multiple myeloma, myeloproliferative disorders, neuroblastoma, plasma cell neoplasm/multiple myeloma, central nervous system lymphoma, intrinsic brain tumors, astrocytic brain tumors, gliomas, and metastatic tumor cell invasion in the central nervous system.

The liposomal delivery system described herein can be used, in principle, with any active pharmaceutical ingredient for the treatment of brain diseases. Non-limiting examples of brain diseases, with suitable medication are discussed below.

Alzheimer’s Disease (AD): Active pharmaceutical ingredients for use in the treatment of AD include: i) Acetylcholinesterase inhibitors (AChEI) such as donepezil, galantamine, rivastigmine, tacrine ii) NMDA receptor antagonists such as memantine.

Parkinson's Disease: Active pharmaceutical ingredients for use in the treatment of Parkinson’s disease include: i) dopamine precursors such as Levodopa, and combinations of levodopa with: carbidopa, COMT inhibitors (for example entacapone and tolcapone), amantadine ii) dopamine agonists such as bromocriptine, pergolide, pramipexole, ropinirole, piribedil, cabergoline, apomorphine and lisuride iii) MAG-B inhibitors such as safinamide, selegiline and rasagiiine iv) Anticholinergics such as trihexyphenidyl and benzatropine.

Multiple sclerosis (MS): Active pharmaceutical ingredients For use in the management of MS include: i) glucocorticoids ( example prednisolone, prednisone, dexamethasone), corticotropin; ii) disease-modifying medications : interferons such as interferon beta-la, interferon beta-1 b, and peginterferon beta-1 a. Giatiramer acetate, immunosuppressants (such as dimethyl fumarate fingolimod, teriflunomide, natalizumab, mycophenolate mofetil), azathioprine inteleucin inhibitors (daciizumab), other monoclonal antibodies (ocrelizumab, alemtuzumab), immunostimulants (giatiramer), rituximab; iii) others : valacyclovir, dalfampridine, cladribine, mitoxantrone, cyclophosphamide.

Brain cancer and tumors: Brain tumors may include: Anaplastic Astrocytoma, Anaplastic Oligodendroglioma, Angioblastoma, Glioblastoma Multiforme, Malignant Glioma, Neuroblastoma, Pituitary Tumor etc. Suitable active pharmaceutical ingredients for use in the treatment and/or management of brain tumors are the following: i) temozoiomide, procarbazine, lomustine, everolimus, cyclophosphamide, carmustine, methotrexate, cisplatin, vincristine, interferon alfa-2b, bevacizumab, hydroxyurea, bromocriptine, octreotide, pegvisomant, lanreotide and pasireotide.

Other very common active pharmaceutical ingredients for use in the treatment of cancer include the following: (ii) antiproliferative/antineopiastic drugs and combinations thereof, as used in medical oncology such as alkylating agents (for example cis-piatin, carbopiatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busuiphan and nitrosoureas); antimetabolites (for example antifolates such as fluoropyrimidines like 5-fluorouracil and tegafur, raltitrexed, methotrexate, cytosine arabinoside, hydroxyurea and gemcitabine); antitumour antibiotics (for example anthracyclines like adriamycin, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin and mithramycin); antimitotic agents (for example vinca alkaloids like vincristine, vinblastine, vindesine and vinorelbine and taxoids like paclitaxel and taxotere); and topoisomerase inhibitors (for example epipodophyllotoxins like etoposide and teniposide, amsacrine, topotecan and camptothecins); (iii) cytostatic agents such as antioestrogens (for example tamoxifen, toremifene, raloxifene, droioxifene and iodoxyfene), oestrogen receptor down regulators (for example fulvestrant), antiandrogens (for example bicalutamide, flutamide, nilutamide and cyproterone acetate), LHRH antagonists or LHRH agonists (for example goserelin, leuprorelin and buserelin), progestagens (for example megestrol acetate), aromatase inhibitors (for example anastrozoie, letrozoie, vorazole and exemestane) and inhibitors of 5-reductase such as finasteride; (iv) anti-invasion agents (for example c-Src kinase family inhibitors like 4-(6-chloro-2,3 -methyienedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yioxyquinazoline (AZD053Ö; International Patent Application WO 01/94341) and /V-(2-chloro-6-methylphenyi)-2-{6-[4-(2- hydroxyethy!)piperazin~1-yl]-2-methyipyrimidin-4-yiamino}thiazo!e~5-carboxamide (dasatinib, BMS-354825; J. Med. Chem. 2004, 47, 8658-6661), and metalloproteinase inhibitors like marimastat and inhibitors of urokinase plasminogen activator receptor function); (v) inhibitors of growth factor function: for example such inhibitors include growth factor antibodies and growth factor receptor antibodies (e.g. the anti~erbB2 antibody trastuzumab [Herceptin™] and the anti-erbB1 antibody cetuximab [C225]>; such inhibitors also include, for example, tyrosine kinase inhibitors, e.g. inhibitors of the epidermal growth factor family (such as EGFR family tyrosine kinase inhibitors including ./V-(3-chloro-4~fluorophenyl)~7~methGxy-6-(3-morpholinopropoxy)quinazolin-4-amine (gefitinib, ZD 1839), /V-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine (erlotinib, OSI-774) and 6-aeryiamido-A/-(3-ch!oro-4-fiuorophenyi)-7-(3-morphoiinopropoxy)quinazolin-4-amine (Ci 1033) and erbB2 tyrosine kinase inhibitors such as lapatinib), inhibitors of the hepatocyte growth factor family, inhibitors of the platelet-derived growth factor family such as imatinib, inhibitors of serine/threonine kinases (for example Ras/Raf signalling inhibitors such as farnesyi transferase inhibitors, for example sorafenib (BAY 43-9006)) and inhibitors of ceil signalling through MEK and/or through the PI3K, mTOR and AKT kinases pathway; (vi) antiangiogenic agents such as those which inhibit the effects of vascular endothelial growth factor, (for example the anti-vascular endothelial cel! growth factor antibody bevacizumab (Avastin™) and VEGF receptor tyrosine kinase inhibitors such as 4-(4-bromo-2-fluoroani!ino)-6-methoxy-7-(1-methylpiperidin-4-yimethoxy)quinazo!ine (ZD8474; Example 2 within WO 01/32651), 4-(4-fluoro-2~methyiindol-5~y!oxy)-6-methoxy-7-(3-pyrroiidin-1- ylpropoxy)quinazoline (AZD2171; Example 240 within WO 00/47212), vatalanib (PTK787; WÖ 98/35985) and SUi 1248 (sunitinib; WO 01/60814), and compounds that work by other mechanisms (for example linomide, inhibitors of integrin ανβ3 function and angiostatin)); (vii) vascular damaging agents such as combretastatin A4 and compounds disclosed in International Patent Applications WO 99/02166, WO 00/40529, WO 00/41669, WO 01/92224, WO 02/04434 and WO 02/08213; (viii) chromatin modifying agents that allow reversal of epigenetic alterations involved in carcinogenesis, for example, DNA demethylating agents such as 5' azacytidine and decitabine (5-aza-2’-deoxycytidine, dezocitidine) and deacetylase inhibitors such as vorinostat (suberoylanilide hydroxamic acid, Zolinza) and depsipeptide (romidepsin, Istodax); (ix) bisphosphonates, such as clodronate, aledronate, zoledronic acid, ibandronate and pamidronate; (x) aminoglycosides, such as streptomycin, kanamycin, neomycin and gentamicin. Pharmaceutically-aceeptable salts or solvates of any of these compounds are also included.

Other brain diseases include: a) Amyotrophic lateral sclerosis (ALS) (Riluzole and edaravone are active pharmaceutical ingredients that may be used in the treatment of ALS disease). b) Essential tremor (beta blockers: propranolol, nadolol and timolol are active pharmaceutical ingredients that may be used in the treatment of essential tremors). c) Huntington’s disease (suitable active pharmaceutical ingredients for use in the treatment of Huntington’s disease are: chorea reducing drugs, such as tetrabenazine, neuroleptics and benzodiazepines). d) achado-Joseph disease (symptomatic therapy using antispasmodic drugs (baclofen) may be undertaken. The Parkinsonian symptoms can be treated with levodopa therapy) e) Wilson Disease (may be treated with copper chelators) f) Glaucoma (active pharmaceutical ingredients that may be used in the treatment of Glaucoma include: i) prostaglandin analogs, such as latanoprost, bimatoprost and travoprost. ii) topical beta-adrenergic receptor antagonists, such as timolol, levobunolol, and betaxolol iii) alpha2-adrenergic agonists, such as brimonidine and apraclonidine iv) miotic agents (parasympathomimetics), such as pilocarpine v) acetylcholinesterase inhibitors are used in chronic glaucoma, such as echothiophate and vi) carbonic anhydrase inhibitors, such as dorzolamide, brinzolamide, and acetazolamide, g) Hereditary optic neuropathy (Leber) h) Retinitis pigmentosa (supplements such as Vitamin A, DHA, and Lutein can be used to delay the progression of retinitis pigmentosa). i) Meningitis -1) Bacterial meningitis can be treated with cephalosporins (such as cefotaxime or ceftriaxone, and ceftazidime), dexamethasone, ceftriaxone, vancomycin, meropenem, cefotaxime, sulfamethoxazole / trimethoprim, triamcinolone, gentamicin, ceftazidime, metronidazole, rifampin, amikacin, cefuroxime, chloramphenicol, ampicillin, ampiciilin / sulbactam, cilastatin / imipenem, oxacillin, piperacillin, tobramycin, nafcillin, penicillin g potassium, penicillin g sodium, II) Fungal meningitis can be treated with antifungal agents such as amphotericin B and flucytosine; Antifungal agents that may be useful in treating infections include: fluconazole, flucytosine, voriconazole, clotrimazole, econazole nitrate, miconazole, terbinafine, flucoazole, ketoconazoie, amphotericin. Lymphomatous meningitis: cytosine arabinoside (ara-C); III) Viral meningitis (acyclovir is used to treat Herpes Simplex Encephalitis, the only viral meningitis which can be treated to this date). j) inflammatory brain diseases (suitable active pharmaceutical ingredients for use in the treatment of an inflammatory disease include salicylates (such as aspirin, diflunisal, salicylic acid or salsalate), propionic acid derivatives (such as ibuprofen, dexibuprofen, naproxen, fenoprofen, ketoprofen, dexketoprofen, flurbiprofen, oxaprozin or loxoprofen), acetic acid derivatives (such as indomethacin, tolmetin, suiindac, etodolac, ketorolac, diclofenac, aceciofenac, or nabumetone), enolic acid (Oxicam) derivatives (such as piroxicam, meloxicam, tenoxicam, droxicam, iornoxicam or phenylbutazone (Bute)), anthranilic acid derivatives (such as mefenamic acid, meclofenamic acid, flufenamic acid or tolfenamic acid), selective COX-2 inhibitors (such as celecoxib, parecoxib, etoricoxib or firocoxib), sulfonanilides (such as nimesulide), clonixin, licofelone, H-harpagide, misoprostol, esomeprazole, lansoprazole and famotidine. Pharmaceutically-acceptable salts or solvates of any of these compounds are included. Steroidal anti-inflammatory agents include: amcinonide, betamethosone diproprionate, clobetasol, clocortolone, dexamethasone, diflorasone, dutasteride, flumethasone pivalate, flunisolide, flucinolone acetonide, flucinonide, fiuorometholone, fluticasone propionate, flurandrenoiide and hydroflumethiazide k) Psychotic disorders (Psychotic disorders including severe anxiety, severe depression, Asperger syndrome, bipolar disorder, borderline personality disorder, insomnia, mania, obsessive compulsive disorder, paranoia, post-traumatic stress disorder, tic disorder, Tourette’s syndrome, schizophrenia etc. can be treated or managed by the active pharmaceutical ingredients listed below: i) atypical antipsychotics such as quetiapine olanzapine, aripiprazole and brexpiprazole; ii) miscellaneous antipsychotic agents (examples are pimozide, lithium, molindone, loxapine and haloperidol); iii) Phenothiazine antipsychotics such as trifluoperazine, chiorpromazine, perphenazine, fluphenazine, prochlorperazine and thioridazine; iv) thioxanthenes such as thiothixene; Other pharmaceutical ingredients that may be used in the treatment of depression are :

Doxepin, clomipramine, bupropion, amoxapine, nortriptyline, citalopram, duloxetine, trazodone, venlafaxine, selegiline, perphenazine and amitriptyline, desveniafaxine, levomiinacipran, lurasidone, isocarboxazid, phenelzine, desipramine, paroxetine, tranylcypromine fluoxetine, mirtazapine, nefazodone, trimipramine, vortioxetine, vilazodone, protriptyline, sertraline l) Narcolepsy (central nervous system stimulants such as methylphenidate, amphetamine, dextroamphetamine and modafinil can be used) m) Epilepsy,7 Seizures (Acetazolamide, carbamazepine, ciobazam, clonazepam, eslicarbazepine acetate, ethosuximide, gabapentin, lacosamide, lamotrigine, levetiracetam, nitrazepam, oxcarbazepine, perampanel, piracetam, phenobarbital, phenytoin, pregabalin, primidone, rufinamide, sodium valproate, stiripentol, tiagabine, topiramate, vigabatrin, zonisamide, valproate can be used) n) Cranial nerve disorders (Crania! nerve disorders such as trigeminal neuralgia can be treated with carbamazepine (anticonvulsant), baclofen, lamotrigine, oxcarbazepine, phenytoin, gabapentin and pregabaiin).

Other brain diseases with no specific treatment include: sina! muscular-atrophy, Progressive supranuclear palsy (Steele Richardson-Olszewski syndrome), multi-system atrophy, shy-Drager syndrome, spinocerebellar ataxia (SCA), lewy-body disease, Hailervorden-Spatz disease, Creutzfeld-Jakob-disease, Pick’s disease (frontotemporal dementia), Friedreich ataxia, Stargardt disease (macular degeneration), Keams- Sayre syndrome, olivopontocerebellar degeneration, paraneoplasticcerebra! syndromes.

The liposomes and/or compositions described herein can be administered to the subject by any conventional route, including injection or by gradual infusion over time. The administration may, for example, be by infusion or by intramuscular, intravascular, intracavity, intracerebral, intralesional, rectal, subcutaneous, intradermal, epidural, intrathecal, percutaneous administration.

The liposomes and/or compositions described herein may be in any form suitable for the above modes of administration. For example, compositions comprising liposomes may be in form Suitable for injection (e.g. i.v. injection). As further examples, suitable forms for parenteral injection (including, subcutaneous, intramuscular, intravascular or infusion) include a sterile solution, suspension or emulsion; suitable forms for topical administration include an ointment or cream; and suitable forms for rectal administration include a suppository. Alternatively, the route of administration may be by direct injection into the target area, or by regional delivery or by local delivery. The identification of suitable dosages of the compositions of the invention is well within the routine capabilities of a person of skill in the art.

The liposomes and/or compositions described herein are for administration in an effective amount. An “effective amount” is an amount that alone, or together with further doses, produces the desired (therapeutic or non-therapeutic) response. The effective amount to be used will depend, for example, upon the therapeutic (or non-therapeutic) objectives, the route of administration, and the condition of the patient/subject. For example, the suitable dosage for a given patient/subject will be determined by the attending physician (or person administering the composition), taking into consideration various factors known to modify the action of the composition of the invention for example severity and type of brain malignancy, body weight, sex, diet, time and route of administration, other medications and other relevant clinical factors. The dosages and schedules may be varied according to the particular condition, disorder or symptom the overall condition of the patient/subject. Effective dosages may be determined by either in vitro or in vivo methods.

The selective targeting of the liposomes described herein to the BBB enables the administration of reduced dosages of cargo (e.g. active pharmaceutical ingredients) to a subject whilst maintaining a comparable total level of uptake of those cargos (e.g. active pharmaceutical ingredients) in the targeted cells of the body when compared to treatments which do not involve the liposomes described herein.

In embodiments of the methods which involve delivery of a cargo to a patient, the amount of the cargo (e.g. active pharmaceutical ingredient) that is administered to the patient may be less than 50% (by weight) of the standard dose. Preferably the amount is less than 40%, less than 30%, less than 20%. More preferably, the amount of the cargo (e.g. active pharmaceutical ingredient) that is administered to the patient is less than 10% (by weight) of the standard dose. Still more preferably, the amount of the cargo (e.g. active pharmaceutical ingredient) that is administered to the patient is less than 5%, such as less than 2% or less than 1%, (by weight) of the standard dose. In preferred embodiments of the methods of the invention, the amount of the cargo (e.g. active pharmaceutical ingredient) that is administered to the patient is at least 0.1% (by weight) of the standard dose.

The methods of the invention are advantageous as they enable the administration to the patient of an amount of the cargo/drug that is much lower than (for example, less than 10% of) the standard dose. This, in turn, reduces the risk of the subject experiencing side-effects due to the cargo/drug. The term “standard dose” refers to the dose that is considered (e.g. by medical professionals) to be routinely suitable for use in treating the disease from which the patient is suffering. Standard doses are detailed in national formularies and pharmacopoeia, for example the US pharmacopoeia, the British pharmacopoeia and the European pharmacopoeia, as well as other sources such as Martindale “The Complete Drug Reference”, Pharmaceutical Press, 38th Edition, 2014, London, UK. Each of these documents is hereby incorporated by reference. Dosages can also be found in the Summary of Product Characteristics that is associated with the marketing authorisations that are awarded by the European Medicines Agency or by many national competent authorities. Additional information is also available from various web-based sources, including www.drugs.com. In one embodiment, the term “standard dose” refers to the dose specified in the European pharmacopoeia for the disease or condition that is to be treated.

The skilled person would appreciate that a “standard dose” may refer to the amount of the cargo (e.g. active pharmaceutical ingredient (or a prodrug thereof)) that is to be administered to a patient over a particular period of time. For example, a cargo (e.g. active pharmaceutical ingredient) may be administered periodically (e.g. in one, two three or four portions) over the course of a 24-hour period, a 48-hour period or longer. A cargo/drug may also be administered in a continuous manner (e.g. via an intravenous drip) over a prolonged period of time, such as a few hours. In each case, methods involving administering to a patient an amount of cargo/drug over a given period of time may administer less than 50% by weight (e.g. less than 40%, 30%, 20%, 10%, 5%) of the standard dose that is typically administered over the same duration.

Similarly, where the standard dose may vary depending on the nature of the disease or on the patient to be treated, e.g. where the dose is reduced for paediatric use or due to limited tolerance by the patient, these methods involve administering to a patient an amount of cargo/drug that may be less than 50% by weight (e.g. less than 40%, 30%, 20%, 10%, 5%) of the lowest dose that is typically administered for such a patient.

It may also be the case that there is no single accepted dose for the treatment of a given disease, but that a range of doses is considered suitable. In such cases, the dose to be administered may be less than 50% by weight (e.g. less than 40%, 30%, 20%, 10%, 5%) of the lowest of those accepted doses. That is, in a preferred embodiment, the methods of the invention involve administering to a patient an amount of cargo/drug that may be less than 50% by weight (e.g. less than 40%, 30%, 20%, 10%, 5%) of the lowest standard dose.

The compositions of the present invention are advantageously presented in unit dosage form. The discovery that delivery of low doses of cargo (e.g. active pharmaceutical ingredients) may be used due to the selective targeting of the liposomes to the BBB means that novel low-dose formulations may be prepared for use by medical professionals. Thus, there is provided a unit dosage form comprising a liposome composition as defined herein, wherein the amount of the cargo (e.g. active pharmaceutical ingredient) that is present in the unit dosage form may be less than 50% by weight (e.g. less than 40%, 30%, 20%, 10%, 5%) of the standard dose for that cargo (e.g. active pharmaceutical ingredient). The cargo used in said unit dosage form may be any of the cargoes disclosed herein.

The unit dosage form may comprise any of the cargoes (e.g. active pharmaceutical ingredients) mentioned herein, but may typically contain a quantity of at least one of those cargoes (e.g. active pharmaceutical ingredients) which is greatly reduced as compared to the standard doses specified in national formularies and pharmacopoeia, as described hereinbefore. Where a particular cargo (e.g. active pharmaceutical ingredient) may be administered to patients at a range of known doses (which may vary depending on the disease and patient to be treated), it is preferred that the amount of cargo (e.g. active pharmaceutical ingredient) in the unit dose form is lower than the lowest of the known doses, preferably at or below 50% of that lowest dose. The dose of the liposomes that is administered will vary with the exact composition of the liposome.

When the liposomes (or compositions comprising the liposomes) are (systemicaIly (e.g. i.v)) administered to a subject, the liposomes selectively target to the endothelial cells that make up the blood brain barrier. The proportion of liposomes that target to the BBB will increase as the time after (systemic (e.g. i.v.)) administration increases. The liposomes may target rapidly tot the BBB such that at least 10% by weight of the liposomes (% injection dose (i.e. % ID)) reach the BBB within two hours (e.g. within 1 hour) of systemic administration of the liposomes to the subject. Preferably, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, or at least 50% weight percent of liposomes (% ID) reach the BBB within 2 hours (e.g. within 1 hour) post i.v. injection. Accordingly, by “selective targeting” to the BBB, it is intended to include at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, or at least 50% weight percent of liposomes (% ID) reaching the BBB within 2 hours (e.g. within 1 hour, within 30 minutes, within 20 minutes, within 10 minutes) post i.v. injection.

An alternative means for measuring “selective targeting” to the BBB is by comparing the targeting selectivity for the brain endothelium (the BBB) over systemic endothelium. Preferably, the targeting selectivity for brain endothelium (the BBB) over systemic endothelium is at least >3-fold, at least >5-fold, at least >6-fold, at least >7-fold, at least >8-fold, at least >9-fold, or at least > 10-fold within a time period (e.g. within 2 hours (e.g. within 1 hour, within 30 minutes, within 20 minutes, within 10 minutes) post i.v. injection.

Without wishing to be bound by theory, it is believed that the liposomes may undergo different fates once they reach the BBB, depending on their exact composition e.g. 1) they remain associated with the brain endothelium and are neither taken up by endothelial cells or transcytosed into the CNS; 2) they are internalised by endothelial cells, via e.g. receptor-mediated endocytosis; or 3) they are transcytosed (receptor mediated) across the BBB and released into the CNS.

Accordingly, the liposomes may reach the BBB, where they remain associated with the brain endothelium, without being taken up by the endothelial cells, and without crossing the BBB itself (option 1 above). This may be advantageous in diagnostic methods, where the cargo is an imaging agent, and localization at the BBB provides important information to a clinician. Over time, liposomes localized at the BBB may be degraded and begin to “leak” their cargo, and its release would be localized to the BBB region.

The liposomes described herein may also be taken up by a brain endothelial cell (option 2 above). By “taken up”, it is meant that the liposome is drawn through the walls of the cell to reach the interior of the cell. This allows the liposome to transport substances contained therein (or covalently bound thereto) into the cell. The substances that are to be delivered may potentially be capable of interfering with the regular working of the cell, e.g. by killing the cell, modulating its function or affecting its ability to regulate its growth. In a preferred example, the liposome may contain one or more anti-cancer agents in order to reduce the growth, progression or spread of cancer in a subject suffering therefrom. Preferably the liposomes are used to deliver substances which are membrane impermeable, and so are not transported across the cell membrane (in significant quantities) in the absence of a liposome delivery mechanism.

Alternatively, the liposomes may be transcytsed across the BBB and released into the CNS (option 3 above). Transcytosis is a type of transcellular transport in which various macromolecules are transported across the interior of a cell. Macromolecules are captured in vesicles on one side of the ceil, drawn across the ceil, and ejected on the other side. This mechanism would enable the liposome cargo to cross over the BBB and effect its function within the brain/CNS directly.

Although some off-targeting of the liposomes to the venous endothelium of the embryonic fish is observed, the inventors have found that these off-target effects can be effectively and transiently blocked through a simple treatment (e.g. i.v. injection of dextran sulfate). A subject to be treated with the liposomes described herein may therefore benefit from an additional (separate, simultaneous or sequential) treatment with dextran sulfate. The dextran sulfate may be administered as a pre-treatment (i.e. before the liposomes are administered) or may be co-administered with the liposomes. A person of skill in the art is well aware of conventional methods for administering dextran sulfate to a subject. In addition, they would readily be able to determine appropriate timings for dextran sulfate and liposome administration (wherein the timings must be such that the benefits of the dextran sulfate treatment are not lost e.g. because the time between the two treatments is too long)). A method for delivering a cargo to the blood brain barrier of a subject comprising administering an effective amount of a liposome or composition as described herein is also provided. Thus, the methods described herein do not need to be limited to methods of treatment per se, and also encompass e.g. diagnostic and theranostic methods.

For example, the method may deliver an imaging agent to the BBB of the subject. Different suitable imaging agents have been described elsewhere herein. Where compatible, the methods described above for administration of the liposome/composition during methods of treatment (including the additional administration of dextran sulfate) apply equally to this aspect of the invention.

An in vitro use of a liposome / composition comprising a liposome for delivering a cargo to an endothelial cell is also described. This aspect may be useful for delivery of cargo to endothelial cells in tissue culture (e.g. for increasing cargo uptake into the culture cells, or for increasing the amount of liposome/cargo at close proximity to the endothelial cell surface during cell culture). The previous discussion of e.g. suitable cargo applies equally to this aspect of the invention. A method of making a liposome is also described, the method comprising the steps of: i) selecting a first lipid, ii) selecting a second lipid which combines with the first lipid to make a liposome, wherein phase separation occurs between the first lipid and the second lipid in the liposome; and iii) combining the first lipid and the second lipid, and optionally a cargo, to make the liposome as defined herein. The first lipid, second lipid and cargo are as defined elsewhere herein.

Conventional methods for making liposomes may be used to make the liposomes described herein. By way of example, liposomes may be prepared by various methods from dry lipid films of the desired lipid composition. Common methods include hydration then sonication, hydration then extrusion, detergent depletion, freeze-dried rehydration and reverse-phase evaporation. Suitable methods are known to those skilled in the art and are described, for instance, in Chapter 1 of the book: 'Liposomes: Second Edition' Vladamir Torchilin, Volkmar Weissig, OUP, 2003, the relevant disclosures in which document are hereby incorporated by reference. Liposome formation may be performed at above about 0°C (e.g. room temperature) if the phase transition temperature of the acyl chains (chain melting; gel-to-liquid crystals) is below the freezing point of water.

Liposomes containing an active pharmaceutical ingredient or imaging agent may be prepared by drying a lipid stock solution to form a thin film of lipid, and then hydrating that film with an aqueous solution containing the active pharmaceutical ingredient or imaging agent. This is preferably carried out in the presence of suitable agitation (e.g. stirring). Purified (e.g. distilled) water is typically used to form the aqueous solution containing an active pharmaceutical ingredient or imaging agent. However, certain medical applications may require the use of saline or a buffer solution.

Solutions/liquids may be purged with nitrogen or argon at a suitable stage in the above process, if and as appropriate.

Homogenisation of the liposomal composition may also be required. Homogenisation methods include vigorous mechanical mixing or high speed homogenisation, for instance by means of an Ultra Turrax® (Jankei & Kühnke, Germany). Shaking, vortexing and rolling may also be performed as part of the homogenisation step of the above process. A homogeneous size distribution of the liposomes that are useful in the methods of the invention may be desirable and may be obtained by extrusion through a membrane filter, such as one made of polycarbonate, with a pore size of about 100 nm. Membrane filters (e.g. Nuclepore Track-Etch membranes, Whatman) may be procured from Sigma- Aldrich. Whichever lipid substance (or combination thereof) is used, suitable total amounts/concentrations of lipid(s) that may be employed in the liposomal compositions that are useful in the methods of the invention are in the range of about 1 mg/mL to about 120 mg/mL. Liposomal compositions that may be mentioned include those in which, when the second lipid comprises phospholipid (whether in combination with another lipid or otherwise), the amount of phospholipid(s) in the composition is from about 1 (e.g. 10 about 1) mg/mL to about 120 mg/mL. Typical ranges that may be mentioned include from about 5 mg/mL to about 50 mg/mL. Further, the total amount of phospholipid (when the polar lipid comprises phospholipid) is preferably in the range from about 10 mg to about 50 mg. Methods for preparing freeze-dried liposomal compositions, and methods of reconstituting those formulations prior to use are known to those skilled in the art and are discussed in Chapter 5.4 of the book: 'Liposomes: Second Edition' Vladamir Torchilin, Volkmar Weissig, OUP, 2003. In accordance with the invention, the compositions described herein may be administered intravenously, intramuscularly, subcutaneously, transdermally, topically, or by any other parenteral route, in the form of a pharmaceutical preparation comprising the composition in a pharmaceutically acceptable form. Preferred modes of delivery include intravenous, subcutaneous, and intramuscular delivery.

Conventional methods for microfluidic mixing of reagents for making liposomes of the invention are also well known. Such methods may be performed using e.g. Precision Nanosystems’ NanoAssemblr™ platform technology. Further specific details in respect of encapsulating single AuNPs within liposomes through a microfluidics approach can be found in Witzigmann, D. et al.Formation of lipid and polymer based gold nanohybrids using a nanoreactor approach RSCAdv., 2015,5, 74320-74328.

The liposomal compositions described herein, may be obtained from a suitable freeze-dried formulation. Freeze-dried formulations may themselves be prepared according standard techniques that are known to those skilled in the art, and are advantageous as they allow for convenient, long term storage of the formulation in a form which can be readily converted into one that may be administered to the patient. Such freeze-dried formulations comprise a liposome and either an active pharmaceutical ingredient or an imaging agent, each as defined herein. The amount of that active pharmaceutical ingredient/imaging agent may be less than 50% by weight (e.g. less than 40%, 30%, 20%, 10%, 5%) of the standard dose for that active pharmaceutical ingredient/imaging agent.

Freeze-dried compositions are reconstituted prior to use in order for the composition to be provided in a form which is suitable for administration to a patient. Reconstitution of freeze-dried compositions may be achieved using standard techniques that are known to those skilled in the art.

In a further embodiment, there is provided a kit comprising a freeze-dried liposomal composition as defined herein together with instructions for reconstituting said freeze-dried composition and administering it to a patient. The freeze- dried compositions described herein may contain additional components besides the liposomes, for example lyoprotectants. Suitable lyoprotectants would be known to the skilled person and include disaccharides such as sucrpse, lactose and trehalose.

The liposome compositions described herein may also be supplied to medical professionals in the form of solutions containing the liposomes and the active pharmaceutical ingredient and/or imaging agent, and may be provided in a form which is suitable for administration directly to the subject (e.g. via intravenous injection). A kit is also provided for preparing a liposome described herein. The kit comprises a first lipid and a second lipid, both of which are defined elsewhere herein. The first lipid and the second lipid may be in separate containers in the kit, or they may be in the same container. The kit may further comprise instructions for a user, e.g. to how to make a liposome as described herein. Such instruction can be provided via any medium, e.g., hard paper copy, electronic medium, or access to a database or website containing the instruction. Optionally, the kit further comprises a container containing a cargo as described elsewhere herein. The container with the cargo may be the same container that contains the first lipid (and/or the second lipid) or it may be a separate container. A kit is also provided for preparing a liposome comprising a cargo, as described elsewhere herein. The kit may contain a container with a liposome of the present invention, and, optionally, a container containing a cargo, and/or instructions for a user, e.g. on how to encapsulate the cargo in the liposome or with procedures or information related to using the liposome for one or more applications described herein. The instructions can be provided via any medium, e.g., hard paper copy, electronic medium, or access to a database or website containing the instruction.

The invention is further described in the following Examples. The Examples serve only to illustrate the invention and are not intended to limit the scope of the invention in any way.

EXAMPLES

Liposomes are the most widely investigated nanoparticles for drug delivery applications. The only targeted, liposomal drug delivery technologies approved for clinical use remains the use of long-circulating, doxorubicin-filled liposomes passively targeting solid tumors via the enhanced permeability and retention (EPR) effect - eg. Doxil or Myocet. Targeting efficiencies of these liposomes are typically <1% of the total injected dose (%I.D).

Targeting therapies to the BBB (and often onwards into the brain) specifically, following systemic administration, is currently investigated through receptor mediated ligand targeting. The most commonly cited ligands to achieve this are transferrin (Tf) (or mimics of), insulin (or mimics of), angiopeptide and ApoE fragments (targeting low-density lipoprotein, LDL receptors) and glutathione, each targeting their respective named receptors. None of these receptors are exclusively expressed at the BBB. We have synthesized and tested many of the common ligands used to target the BBB in the embryonic zebrafish model (see Figure 2). As can be seen, liposomes functionalized with these ligands accurately target organs in which their target receptors are highly expressed but none significantly accumulate at the brain endothelium.

More recently components of neurotropic viruses (e.g. rabies virus glycoprotein) have also been implemented. The current state-of-the-art in the targeted treatment of brain cancer is bevacizumab - a monoclonal antibody targeting vascular endothelial growth factor (VEGF). However, recent randomized, double-blind, placebo-controlled clinical trials showed no overall improvement to patient survival rates following this treatment regime.

For these technologies, percentages of injected dose (%ID) reaching the brain are rarely quoted, rather indirect effects of drug delivery (eg. reduction in tumor size). Direct quantification as to the efficiency of targeting is therefore hard to gauge. However, listed are some examples where %ID within the brain (and inclusive of the brain endothelium) is directly quantified: 1) cTfRMAb, a chimeric mAb that binds to the mouse TfR - 1.4% ID - 1 hpi (i.v.) 2) HIRMAb - a fully humanized mAb for the human insulin receptor - approx. 2% ID -2hpi (i.v.)

3) Tf-conjugated to AU NPs - 0.3% ID

Targeting therapies to the BBB (and often onwards into the brain), following systemic administration, is currently investigated by others through receptor mediated ligand targeting. The most commonly cited ligands to achieve this are transferrin (Tf) (or mimics of), insulin (or mimics of), angiopeptide and ApoE fragments (targeting low-density lipoprotein, LDL receptors) and glutathione, each targeting their respective named receptors. None of these receptors are exclusively expressed at the BBB. The inventors have synthesized and tested many of the common ligands used to target the BBB in the embryonic zebrafish model (see Figure 2). As can be seen, liposomes functionalized with these ligands accurately target organs in which their target receptors are highly expressed but none significantly accumulate at the brain endothelium. A novel mechanism is required to selectively target drugs and other cargo such as imaging agents to the BBB.

The inventors have surprisingly identified specific lipids, which when mixed together with a naturally occurring phospholipid, such as DSPC, and formulated into 100nm liposomes, result in selective accumulation of the liposomes at the BBB of embryonic zebrafish following systemic (i.v.) administration (see Figure 1). The targeting selectivity for the brain endothelium (the BBB) over systemic endothelium is > 10-fold. An approximate quantification of the targeting efficiency of the described liposomes to the BBB is 50% I.D. at 2 hours postinjection in the embryonic fish.

Although some off-targeting of the liposomes to the venous endothelium of the embryonic fish is observed, the inventors have found that these off-target effects can be effectively and transiently blocked through a simple treatment (i.v. injection of dextran sulfate).

The zebrafish genome is 70% homologous to humans and crucially brain morphology, organization and expression of key markers for BBB function and integrity is conserved these species.

The inventors have also demonstrated successful encapsulation of small molecule drugs (eg. the cytotoxic drug, doxorubicin) as well as larger cargoes (eg, Au nanoparticles) into these novel liposomes. The invention therefore provides a novel mechanism for selective delivery of cargo to the BBB.

Reagents and General Methods

Reagents - All lipid reagents can be purchased from Avanti Polar Lipids (Alabaster, AL, US). 1,2-dioleoyl-sn-glycero-3-phosphocholine (DOPC), 1,2-distearoyl-sn-glycero-3- phosphocholine (DSPC), 1,2-dioleoyl-sn-glycero-3-phospho-(1’-rac-glycerol) (DOPG), 1,2-distearoyl-sn-glycero-3-phospho-(1 ’-rac-glycerol) (DSPG), 1,2-dioleoyl-sn-glycero-3-phospho-L-serine (sodium salt) (DOPS), 1,2-dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC). 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine-N-(lissamine rhodamine B sulfonyl) (Rhodamine-PE) were purchased from Avanti Polar Lipids (Alabaster, AL, US).

Additional DOPC and DSPC were purchased from Lipoid GmbH. Additional POPC and cholesterol was purchased from Sigma-Aldrich. Dextran sulfate (40kDa) was purchased from Sigma-Aldrich. Doxorubicin hydrochloride (DOX.HCI) was purchased from Cayman Chemical Company (Ann Arbor, Ml, USA).

All solvents were purchased from Biosolve Ltd.

General methods

For synthesis ofPAPAP3: Silica gel column chromatography was performed using silica gel grade 40-63 pm (Merck). TLC analysis was performed using aluminium-backed silica gel TLC plates (60f 254, Merck), visualisation by UV absorption at 254 nm and/or staining with ΚΜπΟλ solution. 1H NMR spectra were measured on a Bruker AV-400MHz spectrometer. Chemical shifts are recorded in ppm. Tetramethylsilane (TMS) is used as an internal standard. Coupling constants are given in Hz.

Liposome characterization·. Particle size and zeta potentials were measured using a Malvern Zetasizer Nano ZS. For DLS, measurements were carried out at room temperature in ddH20 at a total lipid concentration of 100μΜ. For zeta potential measurements, liposome solutions were first diluted in salt (NaCI) solution. Zeta potentials were measured at room temperature, at 500pM total lipid concentration and 10mM NaCI concentration. All reported DLS measurements and zeta potentials are the average of three measurements.

For doxorubicin encapsulation·. Size exclusion chromatography was carried out using illustra™ NAP™ Sephadex™ G-25 DNA grade pre-made columns (GE Healthcare) and used according to the user instructions. UV absorption spectra were measured using a Cary 3 Bio UV-vis spectrometer, scanning from 250nm to 600nm for doxorubicin and at 1 nm intervals. Scan rate: 120 nm/min.

For AuNP encapsulation'. For TEM observation, a drop of the sample was placed onto a nitrocellulose membrane covered TEM copper grid and dabbed dry through the underside of the grid with a tissue. This was then washed 3 times with ddH2O to remove salts from the grid. A drop of uranyl acetate (2% w/v) in H2O was then added and the sample left to dry in the dark. Transmission electron microscopy (TEM) was conducted on a JEOL 1010 instrument with an accelerating voltage of 60 kV.

Confocal microscopy. Confocal z-stacks were captured on a Leica TCS SPE confocal microscope, using a 10x air objective (HCX PL FLUOTAR) or a 40x water-immersion objective (HCX APO L). For whole-embryo views, 3-5 overlapping z-stacks were captured to cover the complete embryo. Laser intensity, gain and offset settings were identical between stacks and sessions. Images were processed and quantified using the Fiji distribution of ImageJ.

CryoEM: cryoEM was performed by using a CryoTitan (FEI Corp, Hillsboro, OR) operating at 300 kV and equipped with a field emission gun (FEG). Cryo-samples were prepared from a 3 pL droplet of sample solution (5mM liposome as prepared above) placed on the grid inside the VitrobotTM chamber at 100% relative humidity and 20°C. Prior to use the TEM grids were glow discharged by a Cressington 208 carbon coater to render them hydrophilic. The samples were blotted to remove excess solution and vitrified by using an automated vitrification robot (VitrobotTM Mark III, FEI Corp).

Standard methods for cryoEM including sample preparation and image analysis, are well known. Details of such methods can be found in Thompson, R.F. etal. ‘An introduction to sample preparation and imaging by cryo-electron microscopy for structural biology’ Methods, 2016, 3-15; Milne, J.L.S. etal. ‘Cryo-electron microscopy: A primer for the non-microscopist’ FEBS J. 2013, 280(1): 28-45; and Cabra, V., Samsó, M. ‘Do’s and Don'ts of Cryo-electron Microscopy: A Primer on Sample Preparation and High Quality Data Collection for Macromolecular 3D Reconstruction’. J. Vis. Exp. (95), e52311, doi:10.3791/52311 (2015).

Zebrafish husbandry and kdrkGFP transgenic lines: Zebrafish (Danio rerio, strain AB/TL) were maintained and handled according to the guidelines from the Zebrafish Model Organism Database (http://zfin.org) and in compliance with the directives of the local animal welfare committee of Leiden University. Fertilization was performed by natural spawning at the beginning of the light period and eggs were raised at 28.5°C in egg water (60 ug/ml Instant Ocean sea salts). The following previously established zebrafish lines were used Tg(kdrl:GFP)s843 (Jin, S.-W. Cellular and molecular analyses of vascular tube and lumen formation in zebrafish. Development 132, 5199-5209 (2005)). EXAMPLE 1: Synthesis of PAPAP3

To a round bottom flask (1Q0mL) containing stirred solution of (+)-3-Amino-1,2-propanediol (100mg, 1.1mmoL, 1eq) in CH2CI2 (~15mL), Oleic Acid (621.5mg, 2.2mmoL, 2eq), EDCI (527.1mg, 2.75mmoL, 2.5eq), DMAP (336mg, 2.75mmoL, 2.5eq), DIPEA (479pL, 2.75mmoL, 2.5eq) were added. After overnight stirring at RT, the reaction mixture was diluted with DCM, washed with sat. NH4CI (~20mL) and brine (~20mL) and subsequently was dried (Na2SO4), filtered in vacuo and concentrated, so the crude compound was obtained. Purification by Column Chromatography (CH2CI2 to 10% EtOAC in CH2CI2) yielded the target material (248.5mg, 0.401 mmol, 36.5%) with a white-ish waxy structure.

Rf: 0.3 (CH2CI2: EtOAc_8:2) 1H NMR (CDCI3, 400MHz) : 0.86-0.89 (t, 6H, CH3), 1.26-1.3 (d, 40H, CH2), 1.61-1.62 (d, 5H, CH2CH2CO), 1.98-2.02 (q, 8H, CH2CH=CHCH2), 2.2-2.25 (t, 2H, CH2CONH), 2.30-2.36 (t, 2H, CH2COO), 3.2-3.27 (m, 1H, NHCH2C(O)HCH2), 3.5-3.6 (m, 1.48H, NHCH2C(O)HCH2), 3.9-4.0 (m, 0.82, NHCH2C(O)HCH2), 4.0-4.1 (q, 1H, NHCH2C(O)HCH2), 4.13-4.2 (q, 1H, NHCH2C(O)HCH2), 4.8-4.9 (m, 0.21H, NHCH2C(O)HCH2 ), 5.29-5.38 (m, 4H, CH2CH=CHCH2), 5.93-5.94 (t, 1H, NH) (see Figure 3). ESI-HRMS: found m/z 620.56 [M+H]+, C39H73NO4 requires 620.56, delta=0.1ppm EXAMPLE 2: Formulating ‘empty’ liposomes

Liposomes (without encapsulated drugs) were formulated in ddhhO at a total lipid concentration of 5mM. Individual lipids, as stock solutions (1-10mM) in chloroform, were combined at the desired molar ratios and dried to a film, first under a stream of N2 then >1h under vacuum. Lipid films were hydrated in 1mL ddhhO at >65°C (with gentle vortexing if necessary) to form a multilamellar vesicle solution. Large unilamellar vesicles were formed through extrusion at >65°C (Mini-extruder with heating block, Avanti Polar Lipids, Alabaster, US). Hydrated lipids were passed 11 times through 2 x400 nm polycarbonate (PC) membranes (Nucleopore Track-Etch membranes, Whatman), followed by 11 times through 2 x 100 nm PC pores. All liposomes were stored at 4°C and were stable for at least 1 week.

Methods for liposome formation are well known in the art (for details see e.g. 'Liposomes: Second Edition' Vladamir Torchilin, Volkmar Weissig, OUP, 2003). Notably, chapter 1 specifically covers methods of liposome formulation (eg. hydration then sonication, hydration then extrusion, detergent depletion, freeze-dried rehydration and reverse-phase evaporation.)

All liposomes were stored at 4°C and were stable for at least 1 week EXAMPLE 3: Doxorubicin encapsulation and quantification

Passive loading of doxorubicin·. Lipid films (12.5mM total lipids) were hydrated with an aqueous solution of doxorubicin (5mg/mL, 8.6mM) at >65°C. Unilamellar liposomes were subsequently prepared with extrusion as stated above. Size exclusion chromatography was used as a method to separate liposomes from free doxorubicin. Triton 1% v/v was used to disassemble the liposomes and the amount of encapsulated doxorubicin measured by absorbance of the solution at 495nm and fitting to a pre-determined calibration curve.

The final encapsulated concentration of doxorubicin in DSPC:PAPAP3 liposomes (5mM total lipids) was 55pgmL'1 (5.6% e.e.). Encapsulation efficiency could be increased to 11% if the hydrated lipid mixture + doxorubicin (ie. prior to extrusion) was lyophilised, then rehydrated and extruded.

Full details of the lyophilisation technique that was used can be found in Chaudhury, A., Das, S„ Lee, R. F., Tan, K. B., Ng, W. K., Tan, R. B., & Chiu, G. N. (2012). Lyophilization of cholesterol-free PEGylated liposomes and its impact on drug loading by passive equilibration. International journal of pharmaceutics, 430(1), 167-175.

Cargo may also be loaded using active loading methods known in the art. Full details of such methods can be found in Fritze, A., Hens, F., Kimpfler, A., Schubert, R., & Peschka-Süss, R. (2006). Remote loading of doxorubicin into liposomes driven by a transmembrane phosphate gradient. Biochimica et Biophysica Acta (BBA)-Biomembranes, 1758(10), 1633-1640. EXAMPLE 4: AuNP encapsulation (proof-of principle)

In situ formation ofAuNPs during extrusion·. Lipid films (12.5mM total lipid) were hydrated with 1mL of sodium citrate (10.2mM) at 85°C. The sample was then lyophilized and the formed powder was subsequently hydrated with 1mL of aq. sol of HAuCL (2.5mM).

Extrusion was followed at >65°C as stated above, however in this case only 2 x 100nm PC membranes were used. The sample was passed through the extruder ~8 times. Size exclusion chromatography was used to separate liposomes from free GNPs. Liposomes were visualized with TEM. DSPC:PAPAP3 liposomes containing AuNPs were observed (Figure 4). It is noted that use of TEM (rather than cryo-EM) in this partiulcar experiment resulted in the integrity of the liposomes being lost when drying the samples onto the imagine grid However, the images clearly confirm successful AuNP encapsulation in the imaged liposomes.

Details of appropriate microfluidics methods for encapsulation of single AuNPs in liposomes may be found in Witzigmann, D. et al.Formation of lipid and polymer based gold nanohybrids using a nanoreactor approach RSCAdv., 2015,5, 74320-74328. EXAMPLE 5: Localisation Studies in Zebrafish with variation in liposome formulation

Liposomal formulations were injected into 2-day old zebrafish embryos (52-56hpf) using a modified microangraphy protocol (Weinstein, B. M., Stemple, D. L., Driever, W. & Fishman, M. C. Gridlock, a localized heritable vascular patterning defect in the zebrafish. Nat Med 1, 1143-1147 (1995)). Embryos were anesthetized in 0.01% tricaine and embedded in 0.4% agarose containing tricaine before injection. To improve reproducibility of microangiography experiments, 1 nl volumes were calibrated and injected into the sinus venosus/duct of Cuvier. A small injection space was created by penetrating the skin with the injection needle and gently pulling the needle back, thereby creating a small pyramidal space in which the liposomes and polymers were injected. Successfully injected embryos were identified through the backward translocation of venous erythrocytes and the absence of damage to the yolk ball, which would reduce the amount of liposomes in circulation.

The inventors investigated several different lipid combinations to investigate whether i) liposomes could successfully form and ii) whether formed liposomes would target to the BBB.

The inventors found that when using a mixture of DOPC:PAPAP7 (ie. flipping the saturation to ‘fluid’ phospholipid and ‘rigid’ PAPAP) it was not possible to formulate liposomes (data not shown).

Different PAPAP variants were also tested (notably PAPAP1, PAPAP3, PAPAP4, PAPAP5, PAPAP6 and PAPAP7 - see Figure 5). In these experiments, all PAPAPs were formulated 1:1 with DSPC. All images show liposome associated fluorescence (B/W). Targeting to the BBB is shown in these 2 day-old fish for PAPAP3, PAPAP4, PAPAP5, and PAPAP7 containing liposomes, to varying extents. More effective targeting to the BBB has also been observed by the inventors at later developmental stages (3dpf- days post fertilization onwards).

Figures 5 and 6 show that trichain variants (PAPAP 1 and PAPAP6) do not target the BBB (PAPAP6 also does not form stable liposomes). Di-ester variant (PAPAP 4) shows some binding at the BBB. Phosphate analogue (PAPAP 5) demonstrates a strong off-target to venous endothelial cells (almost certainly due to the negative charge) but also binds at the BBB (see Figure 5). Saturated FA variant (PAPAP 7) shows some binding at the BBB (see Figure 5).

The white arrow in Figure 5 highlights PAPAP5 binding to venous endothelial cells. This is evident from what appears as a ‘marbling’ effect of liposome binding within these blood vessels (and continues through the trunk of the fish). This binding corresponds to an off-target interaction with endothelial cells primarily in the mammalian liver and spleen (ie. the RES - reticuloendothelial cell system). However, binding to the BBB is also observed for the PAPAP5-containing liposomes.

The inventors have shown that different regioisomers (and a mixture of regioisomers) of PAPAP3 can be used with an appropriate co-formulant to generate liposomes that target to the BBB. For example, an 80:20 ratio of PAPAP3 regioisomers is routinely used herein and is shown to target to the BBB effectively. In addition, the inventors have tested >90% pure 1° regioisomer of PAPAP3 and this also targets the BBB effectively (data not shown).

The data shown herein illustrates that a number of different lipid combinations may be used. For example, from the data shown herein, it appears that, for the “first lipid” (e.g. PAPAP), a di-chain is necessary (and a tri-chain is ineffective).

Molar ratio of co-formulant lipid ("second lipid” herein) and PAPAP ("first lipid” herein):

The inventors also tested liposome formations using different molar ratios of the two lipids. In these experiments the molar ratios of DSPC:PAPAP3 were varied as described below.

It was found that liposomes generated from a 3:1 molar ratio of DSPC:PAPAP3 (ie. 25% PAPAP3) accumulated at the BBB (see Figure 7). It was also found that liposomes generated from a 9:1 molar ratio of DSPC:PAPAP3 (i.e. 10% PAPAP3) also accumulate at the BBB (see Figure 8). Conversely, the inventors found it difficult to successfully formulate liposomes using a 1:3 molar ratio of DSPC:PAPAP3 (i.e. 75% PAPAP3) (data not shown). These data show an upper limit of PAPAP content of 75%, with an as yet undetermined lower limit of PAPAP.

In other words, a range of molar ratios of co-formulant: PAPAP may be used, from between 9:1 to 1:3, preferably from 3:1 to 1:1, with the most preferable ratio being 1:1.

Co-formulant lipids A number of different co-formulant lipids (described herein as “second lipid”) were also tested. In these experiments, all liposomes formulated 1:1 with PAPAP3. All images show liposome-associated fluorescence (B/W). Whole fish images are included to illustrate vein/macrophage targeting.

Use of DSPG (C18:0, saturated, anionic) in a 1:1 ratio with PAPAP3 generated liposomes with low level binding at the BBB and mild off-target interaction with veins (white arrow). Mostly freely circulating (see Figure 9).

Use of DOPS (C18:1, unsaturated, anionic) in a 1:1 ratio with PAPAP3 generated liposomes with no significant binding at the BBB and strong off-target interaction with veins (white arrow) (see Figure 10).

Use of DPPC (C16:0, saturated, zwitterionic) in a 1:1 ratio with PAPAP3 generated liposomes that bound at the BBB - however is potently taken up by plasma exposed macrophages (large white spots) - this will likely correspond to uptake by liver resident macrophages (Kupffer cells) in mammals (see Figure 11).

Use of DMPC (C14:0, saturated, zwitterionic) in a 1:1 ratio with PAPAP3 generated liposomes with very low level binding at the BBB - some uptake by plasma exposed macrophages - mostly freely circulating (see figure 12). Notably, the phase transition temperature of DMPC (below which the bilayer is rigid (gel state) and above which it is fluid (liquid crystalline) is 28°C. The experimental temperature is 28°C.

Use of DOPC (C18:1, unsaturated, zwitterionic) in a 1:1 ratio with PAPAP3 generated liposomes with no significant binding at the BBB and a strong off-target interaction with veins (white arrow) (see Figure 13).

These data show that different co-formulant lipids (described herein as “second lipid”) may be used. The experiments performed indicate that the co-formulant lipid may be any (phospho)lipid with a phase transition temperature above 37°C, ideally with a zwitterionic headgroup. Most ideally, the co-formulant is phosphatidylcholine.

The inventors have therefore identified a number of different variations on the liposome formulation that will selectively target to the BBB, with different levels of efficiency/off target effects. The optimal formulation tested is DSPC:PAPAP3. As shown in Figure 14, the accumulation at the BBB (blue arrow) for this formulation is very, very apparent compared to the other formulations tested. There is however a significant off-target to the veins (white arrow) ie. liver. This off-target effect is reduced with a further treatment with dextran-sulphate (data not shown).

Claims

E Liposoom, omvattende: a. een eerste lipide met formule I:E Liposome, comprising: a. A first lipid of formula I:

waarbij R1 en R2 onafhankelijk geselecteerd zijn uit H, Cio-Cso-alkyl, C10-C30-alkenyl, Cio-Cso-alkynyl, C(0)-Cio-C3o-alkyl, C(0)-Cio-C3o-alkenyl, en C(0)-Cio-Cso-alkynyl; R3 onafhankelijk geselecteerd is uit H, Cio-C3o-alkyl, Cio-C3o-alkenyl, C10-C30-alkynyl, waarbij een enkele van R1, R2 en R3 gelijk is aan H; X1 en X2 elk onafhankelijk geselecteerd zijn uit -O-, -S- en -NR4-; X3 onafhankelijk geselecteerd is uit een binding, -O-, -S- en -NR4-, -C(O)-, -C(O)O-, -OC(O)-, -C(O)- NR4-, -NR4C(O)- en -OP(O)2O-; waarbij, indien R3 gelijk is aan Η, X3 geen binding is; R4 onafhankelijk geselecteerd is uit H en Ci-C-t-alkyl; elke n een geheel getal is dat onafhankelijk geselecteerd is uit het bereik van 1 tot 4, en bij voorkeur gelijk is aan 1 of aan 2; of een farmaceutisch aanvaardbaar zout daarvan; en b. een tweede lipide, waarbij er zich een fasescheiding voordoet tussen de eerste lipide en de tweede lipide in het liposoom.wherein R 1 and R 2 are independently selected from H, C 10 -C 30 alkyl, C 10 -C 30 alkenyl, C 10 -C 30 alkynyl, C (O) -C 10 -C 30 alkyl, C (O) -C 10 -C 30 alkenyl, and C (O) -C 10 -C 30 alkynyl; R 3 is independently selected from H, C 10 -C 30 alkyl, C 10 -C 30 alkenyl, C 10 -C 30 alkynyl, wherein a single of R 1, R 2 and R 3 is H; X1 and X2 are each independently selected from -O-, -S- and -NR4-; X 3 is independently selected from a bond, -O-, -S- and -NR 4 -, -C (O) -, -C (O) O-, -OC (O) -, -C (O) - NR 4 - , -NR 4 C (O) - and -OP (O) 20 -; wherein, if R3 is Η, X3 is not a bond; R 4 is independently selected from H and C 1 -C 1- alkyl; each n is an integer independently selected from the range of 1 to 4, and preferably equal to 1 or 2; or a pharmaceutically acceptable salt thereof; and B. a second lipid, wherein a phase separation occurs between the first lipid and the second lipid in the liposome.

2. Liposoom volgens conclusie 1, waarbij de lipide met formule I een lipide is met formule II:The liposome according to claim 1, wherein the lipid of formula I is a lipid of formula II:

waarbij X3 gelijk is aan -NHC(O)- of aan -OC(O)-;wherein X 3 is -NHC (O) - or -OC (O) -;

waarbij R1 en R2 onafhankelijk geselecteerd zijn uit H, C(0)-Cio-C3o-alkenyl, en C(O)-Cio-Cso-alkynyl; R3 onafhankelijk geselecteerd is uit H, Cio-C3o-alkenyl, Cio-C.3o-alkynyl; waarbij een enkele van R1, R2 en R3 gelijk is aan H.wherein R 1 and R 2 are independently selected from H, C (O) -C 10 -C 30 alkenyl, and C (O) -C 10 -C 30 alkynyl; R 3 is independently selected from H, C 10 -C 30 alkenyl, C 10 -C 30 alkynyl; wherein a single of R1, R2 and R3 is H.

3. Liposoom volgens conclusie 1 of conclusie 2, waarbij de eerste lipide is:The liposome according to claim 1 or claim 2, wherein the first lipid is:

of een farmaceutisch aanvaardbaar zout, een regio-isonreer, of een farmaceutisch aanvaardbaar zout van een regio-isomeer daarvan.or a pharmaceutically acceptable salt, a regioisomer, or a pharmaceutically acceptable salt of a regioisomer thereof.

4. Liposoom volgens een der voorgaande conclusies, waarbij de tweede lipide een fosfolipide is, optioneel met de volgende formule III:A liposome according to any one of the preceding claims, wherein the second lipid is a phospholipid, optionally with the following formula III:

waarbij R3 en R5 6 elk onafhankelijk geselecteerd zijn uit C(0)-Cio-C3o-alkyl, C(0)-Cio-C3o-alkenyl, en C(O)-C io-C30-alkynyl; en R7, elke keer dat het voorkomt, onafhankelijk gelijk is aan Cr-Cr-alkyl.wherein R 3 and R 5 are each independently selected from C (O) -C 10 -C 30 alkyl, C (O) -C 10 -C 30 alkenyl, and C (O) -C 10 -C 30 alkynyl; and R 7, each time it occurs, is independently C 1 -C 6 alkyl.

5. Liposoom volgens conclusie 4, waarbij de fosfolipide is geselecteerd uit welke dan ook van fosfatidylcholine (PC), fosfatidylglycerol (PG), fosfatidylserine (PS), fosfatidylethanolamine (PE), fosfatidylglyceriden, fosfatidinezuur (PA), fosfosphingolipiden, of welke combinatie dan ook van de voorgaande.The liposome according to claim 4, wherein the phospholipid is selected from any of phosphatidylcholine (PC), phosphatidylglycerol (PG), phosphatidylserine (PS), phosphatidylethanolamine (PE), phosphatidylglycerides, phosphatidic acid (PA), phosphosphingolipids or any combination of danolipids, also from the above.

6. Liposoom volgens conclusie 5, waarbij de fosfolipide een fosfatidylcholine (PC) is.The liposome of claim 5, wherein the phospholipid is a phosphatidylcholine (PC).

7. Liposoom volgens conclusie 6, waarbij de fosfatidylcholine (PC) is geselecteerd uit de groep die bestaat uit l,2-didecanoyl-sn-glycero-3-fosfocholine (DPPC), 1,2-diërucoyl-sn-glycero-3-fosfocholine (DEPC), l,2-dilinoleoyl-sn-glycero-3-fosfocholine (DLOPC), l,2-dilauroyl-sn-glycero-3-fosfocholine (DLPC), l,2-dimyristoyl-sn-glycero-3-fosfocholine (DMPC), l,2-distearoyl-sn-glycero-3-fosfocholine (DSPC), l-myristoyl-2-palmitoyl-sn-glycero-3-fosfocholine (MPPC), l-myristoyl-2-stearoyl-sn-glycero-3-fosfocholine (MSPC), l-palmitoyl-2-myristoyl-sn-glycero-3-fosfocholine (PMPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-fosfocholine (POPC), l-pahnitoyl-2-stearoyl-sn-glycero-3-fosfocholine (PSPC), l-stearoyl-2-myristoyl-sn-glycero-3-fosfocholine (SMPC), l-stearoyl-2-oleoyl-sn-glycero-3-fosfocholine (SOPC), l-stearoyl-2-palmitoyl-sn-glycero-3-fosfocholine (SPPC), ei-fosfatidylcholine (EPC), soja-PC, hydro-soja-PC (HSPC), hersen-PC, hart-PC, lever-PC, of welke combinatie dan ook van de voorgaande.The liposome according to claim 6, wherein the phosphatidylcholine (PC) is selected from the group consisting of 1,2-didecanoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-dielecoyl-sn-glycero-3 phosphocholine (DEPC), 1,2-dilinoleoyl-sn-glycero-3-phosphocholine (DLOPC), 1,2-dilauroyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycero-3 -phosphocholine (DMPC), 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC), 1-myristoyl-2-palmitoyl-sn-glycero-3-phosphocholine (MPPC), 1-myristoyl-2-stearoyl- sn-glycero-3-phosphocholine (MSPC), 1-palmitoyl-2-myristoyl-sn-glycero-3-phosphocholine (PMPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1 -pahnitoyl-2-stearoyl-sn-glycero-3-phosphocholine (PSPC), 1-stearoyl-2-myristoyl-sn-glycero-3-phosphocholine (SMPC), 1-stearoyl-2-oleoyl-sn-glycero-3 -phosphocholine (SOPC), 1-stearoyl-2-palmitoyl-sn-glycero-3-phosphocholine (SPPC), egg phosphatidylcholine (EPC), soybean PC, hydro-soybean PC (HSPC), brain PC, heart -PC, liver-PC, or any combination of the foregoing.

8. Liposoom volgens conclusie 7, waarbij de fosfolipide l,2-distearoyl-sn-glycero-3-fosfocholine (DSPC) is.The liposome of claim 7, wherein the phospholipid is 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC).

9. Liposoom volgens een der voorgaande conclusies, waarbij de tweede lipide de externe lipide-bi-laag van het liposoom vormt.A liposome according to any one of the preceding claims, wherein the second lipid forms the external lipid bi-layer of the liposome.

10. Liposoom volgens conclusie 9, waarbij een nanodomein van de eerste lipide ge ingekapseld is in de externe lipide-bi-laag van het liposoom.The liposome of claim 9, wherein a nanodomain of the first lipid is encapsulated in the external lipid bi layer of the liposome.

11. Liposoom volgens een der volgende conclusies, waarbij het liposoom in het bezit is van een diameter van de hoofdas van het liposoom die gelegen is in het bereik van ongeveer 50 nm tot ongeveer 250 nm, optioneel waarbij het liposoom in het bezit is van een diameter van de hoofdas van ongeveer 100 nm.The liposome of any one of the following claims, wherein the liposome has a diameter of the major axis of the liposome that is in the range of about 50 nm to about 250 nm, optionally wherein the liposome is in possession of a diameter of the major axis of about 100 nm.

12. Liposoom volgens een der voorgaande conclusies, waarbij de molverhouding van eerste lipide:tweede lipide is gelegen tussen ongeveer 1:9 en ongeveer 3:1, optioneel tussen ongeveer 1:3 en ongeveer 1:1, en bij voorkeur ongeveer 1:1 bedraagt.A liposome according to any one of the preceding claims, wherein the molar ratio of first lipid: second lipid is between approximately 1: 9 and approximately 3: 1, optionally between approximately 1: 3 and approximately 1: 1, and preferably approximately 1: 1 amounts.

13. Liposoom volgens een der voorgaande conclusies, waarbij het liposoom bovendien een lading omvat.A liposome according to any one of the preceding claims, wherein the liposome further comprises a charge.

14. Liposoom volgens conclusie 13, waarbij de lading een werkzame farmaceutische ingrediënt is, waarbij optioneel de werkzame farmaceutische ingrediënt geselecteerd is uit de groep die bestaat uit: een kleine molecule, een peptide, een proteïne, een anorganisch nanodeeltje, een oligonucleotide, of welke combinatie dan ook van de voorgaande.The liposome of claim 13, wherein the charge is an active pharmaceutical ingredient, optionally the active pharmaceutical ingredient being selected from the group consisting of: a small molecule, a peptide, a protein, an inorganic nanoparticle, an oligonucleotide, or which combination of the above.

15. Liposoom volgens conclusie 13, waarbij de lading een beeldvormend middel is, optioneel waarbij het beeldvormende middel is geselecteerd uit: contrastmiddelen voor MRI, radioactieve beeldvormende middelen voor PET/SPECT, paramagnetische nanodeeltjes, fluorescente probes, bioluminescente probes, kwantumpunten, gouden nanodeeltjes, middelen voor optische coherentiethermografie, fluorescente proteïnen, fluorescente/radioactieve latexkralen/polymeren, foto-akoestische beeldvormende middelen (bijvoorbeeld koolstofnanobuisjes), middelen voor Raman-spectroscopie, nanobuisjes, of welke combinatie dan ook van de voorgaande.The liposome according to claim 13, wherein the charge is an imaging agent, optionally wherein the imaging agent is selected from: MRI contrast agents, PET / SPECT radioactive imaging agents, paramagnetic nanoparticles, fluorescent probes, bioluminescent probes, quantum dots, golden nanoparticles, optical coherence thermography agents, fluorescent proteins, fluorescent / radioactive latex beads / polymers, photoacoustic imaging agents (e.g. carbon nanotubes), Raman spectroscopy agents, nanotubes, or any combination of the foregoing.

16. Samenstelling, een liposoom zoals gedefinieerd in een der voorgaande conclusies omvattende.A composition comprising a liposome as defined in any one of the preceding claims.

17. Farmaceutische samenstelling, omvattende een liposoom zoals gedefinieerd in een der conclusies 1 tot en met 15, en een farmaceutisch aanvaardbare of aanvaardbaar excipiënt, adjuvans, verdunningsmiddel, en/of drager.A pharmaceutical composition comprising a liposome as defined in any one of claims 1 to 15, and a pharmaceutically acceptable or acceptable excipient, adjuvant, diluent, and / or carrier.

18. Samenstelling volgens conclusie 16 of conclusie 17, waarbij de samenstelling bovendien ten minste één omvat van: een bewaarmiddel, een antioxidans, een bufferend middel, een anionische polymeer, of welke combinatie dan ook van de voorgaande.The composition of claim 16 or claim 17, wherein the composition further comprises at least one of: a preservative, an antioxidant, a buffering agent, an anionic polymer, or any combination of the foregoing.

19. Liposoom volgens een der conclusies 1 tot en met 15, of een samenstelling die een liposoom zoals gedefinieerd in een der conclusies 1 tot en met 15 omvat, voor gebruik in therapie, diagnostiek en/of theranostiek.A liposome according to any one of claims 1 to 15, or a composition comprising a liposome as defined in any one of claims 1 to 15, for use in therapy, diagnostics and / or theranostics.

20. Liposoom volgens een der conclusies 1 tot en met 14, of een samenstelling die een liposoom volgens een der conclusies 1 tot en met 14 omvat, voor gebruik bij het behandelen van een hersenziekte in een subject dat daaraan behoefte heeft.A liposome according to any of claims 1 to 14, or a composition comprising a liposome according to any of claims 1 to 14 for use in treating a brain disease in a subject in need thereof.

21. Liposoom of samenstelling voor gebruik volgens conclusie 20, waarbij de hersenziekte geselecteerd is uit: de ziekte van Alzheimer, de ziekte van Parkinson, multiple sclerose, hersenkanker, een hersentumor, anryotrofe laterale sclerose (ALS), essentiële tremor, de ziekte van Huntington, de ziekte van Machado-Joseph, glaucoom, erfelijke optische neuropathie (Leber), retinitis pigmentosa, meningitis, vitale meningitis, inflammatoire hersenziekte, een psychotische stoornis, narcolepsie, epilepsie/aanvallen, en een stoornis van de hersenzenuw.The liposome or composition for use according to claim 20, wherein the brain disease is selected from: Alzheimer's disease, Parkinson's disease, multiple sclerosis, brain cancer, a brain tumor, anryotrophic lateral sclerosis (ALS), essential tremor, Huntington's disease , Machado-Joseph disease, glaucoma, hereditary optic neuropathy (Leber), retinitis pigmentosa, meningitis, vital meningitis, inflammatory brain disease, a psychotic disorder, narcolepsy, epilepsy / seizures, and brain nerve disorder.

22. Liposoom of samenstelling voor gebruik volgens conclusie 21, waarbij het subject voorbehandeld is met dextraansulfaat.The liposome or composition for use according to claim 21, wherein the subject is pretreated with dextran sulfate.

23. Liposoom of samenstelling voor gebruik volgens conclusie 21, waarbij het liposoom of de samenstelling bedoeld is voor afzonderlijke, gelijktijdige of sequentiële toediening aan het subject met dextraansulfaat.The liposome or composition for use according to claim 21, wherein the liposome or composition is intended for separate, simultaneous or sequential administration to the subject with dextran sulfate.

24. Werkwijze voor het behandelen van een ziekte, waarbij de werkwijze het toedienen omvat van een therapeutisch werkzame hoeveelheid van een liposoom volgens een der conclusies 1 tot en met 14, of van een samenstelling die een liposoom volgens conclusie 1 tot en met 14 omvat, aan een subject dat daaraan behoefte heeft.A method of treating a disease, the method comprising administering a therapeutically effective amount of a liposome according to any of claims 1 to 14, or of a composition comprising a liposome according to claims 1 to 14, to a subject who needs it.

25. Werkwijze volgens conclusie 24, waarbij de ziekte een hersenziekte is.The method of claim 24, wherein the disease is a brain disease.

26. Werkwijze volgens conclusie 25, waarbij de hersenziekte geselecteerd is uit: de ziekte van Alzheimer, de ziekte van Parkinson, multiple sclerose, hersenkanker, een hersentumor, amyotrofe laterale sclerose (ALS), essentiële tremor, de ziekte van Huntington, de ziekte van Machado-Joseph, glaucoom, erfelijke optische neuropathie (Leber), retinitis pigmentosa, meningitis, vitale meningitis, inflammatoire hersenziekte, een psychotische stoornis, narcolepsie, epilepsie/aanvallen, en een stoornis van de hersenzenuw.The method of claim 25, wherein the brain disease is selected from: Alzheimer's disease, Parkinson's disease, multiple sclerosis, brain cancer, a brain tumor, amyotrophic lateral sclerosis (ALS), essential tremor, Huntington's disease, Machado-Joseph, glaucoma, hereditary optic neuropathy (Leber), retinitis pigmentosa, meningitis, vital meningitis, inflammatory brain disease, a psychotic disorder, narcolepsy, epilepsy / seizures, and a brain nerve disorder.

27. Werkwijze volgens een der conclusies 24 tot en met 26, waarbij de werkwijze het voorbehandelen omvat van het subject met dextraansulfaat, voorafgaand aan de toediening van het liposoom of van de samenstelling.The method of any one of claims 24 to 26, wherein the method comprises pretreating the subject with dextran sulfate prior to administration of the liposome or composition.

28. Werkwijze volgens een der conclusies 24 tot en met 26, waarbij de werkwijze het afzonderlijk, gelijktijdig of sequentieel aan het subject toedienen omvat van het liposoom of van de samenstelling met dextraansulfaat.The method of any one of claims 24 to 26, wherein the method comprises administering the liposome or the dextran sulfate composition separately, simultaneously or sequentially to the subject.

29. Gebruik van een liposoom volgens conclusie 1 tot en met 14, of van een samenstelling die een liposoom volgens conclusie 1 tot en met 14 omvat, voor de bereiding van een geneesmiddel voor de behandeling van een ziekte in een subject dat daaraan behoefte heeft.Use of a liposome according to claims 1 to 14, or of a composition comprising a liposome according to claims 1 to 14, for the preparation of a medicament for the treatment of a disease in a subject in need thereof.

30. Gebaiik volgens conclusie 29, waarbij de ziekte een hersenziekte is.The use of claim 29, wherein the disease is a brain disease.

31. Gebaiik volgens conclusie 30, waarbij de hersenziekte geselecteerd is uit: de ziekte van Alzheimer, de ziekte van Parkinson, multiple sclerose, hersenkanker, een hersentumor, amyotrofe laterale sclerose (ALS), essentiële tremor, de ziekte van Huntington, de ziekte van Machado-Joseph, glaucoom, erfelijke optische neuropathie (Leber), retinitis pigmentosa, meningitis, vitale meningitis, inflammatoire hersenziekte, een psychotische stoornis, narcolepsie, epilepsie/aanvallen, en een stoornis van de hersenzenuw.The method of claim 30, wherein the brain disease is selected from: Alzheimer's disease, Parkinson's disease, multiple sclerosis, brain cancer, a brain tumor, amyotrophic lateral sclerosis (ALS), essential tremor, Huntington's disease, Machado-Joseph, glaucoma, hereditary optic neuropathy (Leber), retinitis pigmentosa, meningitis, vital meningitis, inflammatory brain disease, a psychotic disorder, narcolepsy, epilepsy / seizures, and a brain nerve disorder.

32. Gebaiik volgens een der conclusies 29 tot en met 31, waarbij het subject voorbehandeld is met dextraansulfaat.The use of any one of claims 29 to 31, wherein the subject is pretreated with dextran sulfate.

33. Gebruik volgens een der conclusies 29 tot en met 31, waarbij het liposoom of de samenstelling bedoeld is voor afzonderlijke, gelijktijdige of sequentiële toediening aan het subject met dextraansulfaat.The use according to any of claims 29 to 31, wherein the liposome or composition is intended for separate, simultaneous or sequential administration to the subject with dextran sulfate.

34. Werkwijze voor het afleveren van een lading aan de bloed-hersenen-barrière van een subject, het aan het subject toedienen omvattende van een liposoom volgens conclusies 1 tot en met 15, of van een samenstelling die een liposoom volgens conclusies 1 tot en met 15 omvat.A method of delivering a charge to the blood-brain barrier of a subject, comprising administering to the subject a liposome according to claims 1 to 15, or a composition comprising a liposome according to claims 1 to 15.

35. Werkwijze volgens conclusie 34, waarbij het subject voorbehandeld is met dextraansulfaat.The method of claim 34, wherein the subject is pretreated with dextran sulfate.

36. Werkwijze volgens conclusie 34, waarbij de werkwijze het afzonderlijk, gelijktijdig of sequentieel toedienen omvat aan een subject van het liposoom of van de samenstelling met dextraansulfaat.The method of claim 34, wherein the method comprises administering separately, simultaneously or sequentially to a subject of the liposome or dextran sulfate composition.

37. Gebruik van een liposoom volgens conclusies 1 tot en met 15, of van een samenstelling die een liposoom volgens conclusies 1 tot en met 15 omvat, voor het afleveren van een lading aan de bloed-hersenen-barrière van een subject.Use of a liposome according to claims 1 to 15, or of a composition comprising a liposome according to claims 1 to 15, for delivering a charge to the blood-brain barrier of a subject.

38. Gebruik volgens conclusie 37, waarbij het subject voorbehandeld is met dextraansulfaat.The use of claim 37, wherein the subject is pretreated with dextran sulfate.

39. Gebruik volgens conclusie 37 of conclusie 38, waarbij het liposoom of de samenstelling bedoeld is voor afzonderlijke, gelijktijdige of sequentiële toediening aan het subject met dextraansulfaat.The use of claim 37 or claim 38, wherein the liposome or composition is for separate, simultaneous or sequential administration to the subject with dextran sulfate.

40. In vitro gebruik van een liposoom volgens conclusies 1 tot en met 15, of van een samenstelling die een liposoom volgens conclusies 1 tot en met 15 omvat, voor het afleveren van een lading aan een endotheelcel.40. In vitro use of a liposome according to claims 1 to 15, or of a composition comprising a liposome according to claims 1 to 15, for delivering a charge to an endothelial cell.

41. Werkwijze voor het produceren van een liposoom volgens een der conclusies 1 tot en met 15, de stappen omvattende met: i. het selecteren van een eerste lipide met formule I:A method for producing a liposome according to any of claims 1 to 15, comprising the steps of: i. selecting a first lipid of formula I:

waarbij R1 en R2 onafhankelijk geselecteerd zijn uit H, Cio-Cso-alkyl, C10-C30-alkenyl, Cio-Cso-alkynyl, C(0)-Cio-C3o-alkyl, C(0)-Cio-C3o-alkenyl, en C(O)-Cio-Cso-alkynyl; R3 onafhankelijk geselecteerd is uit H, Cio-C3o-alkyl, Cio-C3o-alkenyl, C10-C30-alkynyl, waarbij een enkele van R1, R2 en R3 gelijk is aan H; X1 en X2 elk onafhankelijk geselecteerd zijn uit -O-, -S- en -NR4-; X3 onafhankelijk geselecteerd is uit een binding, -O-, -S- en -NR4-, -C(O)-, -C(O)O-, -OC(O)-, -C(O)- NR4-, -NR4C(Oj- en -OP(O)2O-; waarbij, indien R3 gelijk is aan Η, X3 geen binding is; R4 onafhankelijk geselecteerd is uit H en Ci-C4-alkyl; elke n een geheel getal is dat onafhankelijk geselecteerd is uit het bereik van 1 tot 4, en bij voorkeur gelijk is aan 1 of aan 2; of een farmaceutisch aanvaardbaar zout daarvan; ii. het selecteren van tweede lipide die gecombineerd kan worden met de eerste lipide om een liposoom te vormen, waarbij er zich een fasescheiding voordoet tussen de eerste lipide en de tweede lipide in het liposoom; en iii. het combineren van de eerste lipide en van de tweede lipide, en optioneel een lading, teneinde het liposoom te produceren volgens een der conclusies 1 tot en met 15.wherein R 1 and R 2 are independently selected from H, C 10 -C 30 alkyl, C 10 -C 30 alkenyl, C 10 -C 30 alkynyl, C (O) -C 10 -C 30 alkyl, C (O) -C 10 -C 30 alkenyl, and C (O) -C 10 -C 30 alkynyl; R 3 is independently selected from H, C 10 -C 30 alkyl, C 10 -C 30 alkenyl, C 10 -C 30 alkynyl, wherein a single of R 1, R 2 and R 3 is H; X1 and X2 are each independently selected from -O-, -S- and -NR4-; X 3 is independently selected from a bond, -O-, -S- and -NR 4 -, -C (O) -, -C (O) O-, -OC (O) -, -C (O) - NR 4 - , -NR 4 C (O 1 - and -OP (O) 2 O -; wherein, if R 3 is Η, X 3 is not a bond; R 4 is independently selected from H and C 1 -C 4 alkyl; each n is an integer independently selected from the range of 1 to 4, and preferably equal to 1 or 2, or a pharmaceutically acceptable salt thereof, ii) selecting a second lipid that can be combined with the first lipid to form a liposome, wherein a phase separation occurs between the first lipid and the second lipid in the liposome, and iii) combining the first lipid and the second lipid, and optionally a charge, to produce the liposome according to any of claims 1 to 15.

42. Kit voor het bereiden van een liposoom volgens een der conclusies 1 tot en met 15, waarbij de kit omvat: a. een eerste lipide met formule I:A kit for preparing a liposome according to any of claims 1 to 15, wherein the kit comprises: a. A first lipid of formula I:

waarbij R1 en R2 onafhankelijk geselecteerd zijn uit H, Cio-Cso-alkyl, C10-C30-alkenyl, Cio-Cso-alkynyl, C(0)-Cio-C3o-alkyl, C(0)-Cio-C3o-alkenyl, en C(O)-Cio-Cso-alkynyl; R3 onafhankelijk geselecteerd is uit H, Cio-Cso-alkyl, Cio-Cso-alkenyl, C10-C30-alkynyl, waarbij een enkele van R1, R2 en R3 gelijk is aan H; X1 en X2 elk onafhankelijk geselecteerd zijn uit -O-, -S- en -NR4-; X3 onafhankelijk geselecteerd is uit een binding, -O-, -S- en -NR4-, -C(O)-, -C(O)O-, -OC(O)-, -C(O)- NR4-, -NR4C(O)- en -OP(O)2O-; waarbij, indien R3 gelijk is aan Η, X3 geen binding is; R4 onafhankelijk geselecteerd is uit H en Ci-C4-alkyl; elke n een geheel getal is dat onafhankelijk geselecteerd is uit het bereik van 1 tot 4, en bij voorkeur gelijk is aan 1 of aan 2; of een farmaceutisch aanvaardbaar zout daarvan; b. een tweede lipide, waarbij de eerste lipide en de tweede lipide geschikt zijn voor een fasescheiding wanneer ze gemengd worden om een liposoom te vormen.wherein R 1 and R 2 are independently selected from H, C 10 -C 30 alkyl, C 10 -C 30 alkenyl, C 10 -C 30 alkynyl, C (O) -C 10 -C 30 alkyl, C (O) -C 10 -C 30 alkenyl, and C (O) -C 10 -C 30 alkynyl; R 3 is independently selected from H, C 10 -C 30 alkyl, C 10 -C 30 alkenyl, C 10 -C 30 alkynyl, wherein a single of R 1, R 2 and R 3 is H; X1 and X2 are each independently selected from -O-, -S- and -NR4-; X 3 is independently selected from a bond, -O-, -S- and -NR 4 -, -C (O) -, -C (O) O-, -OC (O) -, -C (O) - NR 4 - , -NR 4 C (O) - and -OP (O) 20 -; wherein, if R3 is Η, X3 is not a bond; R 4 is independently selected from H and C 1 -C 4 alkyl; each n is an integer independently selected from the range of 1 to 4, and preferably equal to 1 or 2; or a pharmaceutically acceptable salt thereof; b. a second lipid, wherein the first lipid and the second lipid are suitable for a phase separation when they are mixed to form a liposome.

43. Werkwijze volgens conclusie 41, of kit volgens conclusie 42, waarbij de lipide met formule I een lipide is met formule II:The method of claim 41, or the kit of claim 42, wherein the lipid of formula I is a lipid of formula II:

waarbij X’ gelijk is aan -NHC(O)- of aan -OC(O)-; waarbij R1 en R2 onafhankelijk geselecteerd zijn uit H, C(0)-Cio-C3o-alkenyl, en C(O)-Cio-C3o-alkynyl; R3 onafhankelijk geselecteerd is uit H, Cio-Cso-alkenyl, Cio-C3o-alkynyl; waarbij een enkele van R1, R2 en R’ gelijk is aan H.wherein X 'is -NHC (O) - or -OC (O) -; wherein R 1 and R 2 are independently selected from H, C (O) -C 10 -C 30 alkenyl, and C (O) -C 10 -C 30 alkynyl; R 3 is independently selected from H, C 10 -C 30 alkenyl, C 10 -C 30 alkynyl; wherein a single of R1, R2 and R "is H.

44. Werkwijze of kit volgens een der conclusies 41 tot en met 43, waarbij de eerste lipide is:The method or kit of any one of claims 41 to 43, wherein the first lipid is:

of een farmaceutisch aanvaardbaar zout, een regio-isonreer, of een farmaceutisch aanvaardbaar zout van een regio-isonreer daarvan.or a pharmaceutically acceptable salt, a regioisonomer, or a pharmaceutically acceptable salt of a regioisonomer thereof.

45. Werkwijze of kit volgens een der conclusies 41 tot en met 44, waarbij de tweede lipide een fosfolipide is, optioneel met de volgende formule III:The method or kit of any one of claims 41 to 44, wherein the second lipid is a phospholipid, optionally with the following formula III:

waarbij R’ en R6 elk onafhankelijk geselecteerd zijn uit C(0)-Cw-C3o-alkyl, C(0)-Cw-C3o-alkenyl, en C(0)-Cio-C3o-alkynyl; en R7, elke keer dat het voorkomt, onafhankelijk gelijk is aan Ci-C4-alkyl.wherein R 1 and R 6 are each independently selected from C (O) -C 8 -C 30 alkyl, C (O) -C 8 -C 30 alkenyl, and C (O) -C 10 -C 30 alkynyl; and R 7, each time it occurs, is independently C 1 -C 4 alkyl.

46. Werkwijze of kit volgens conclusie 45, waarbij de fosfolipide is geselecteerd uit welke dan ook van fosfatidylcholine (PC), fosfatidylglycerol (PG), fosfatidyl serine (PS), fosfatidylethanolamine (PE), fosfatidylglyceriden, fosfatidinezuur (PA), fosfosphingolipiden, of welke combinatie dan ook van de voorgaande.The method or kit of claim 45, wherein the phospholipid is selected from any of phosphatidylcholine (PC), phosphatidylglycerol (PG), phosphatidyl serine (PS), phosphatidylethanolamine (PE), phosphatidylglycerides, phosphatidic acid (PA), phosphosphingolipids, any combination of the foregoing.

47. Werkwijze of kit volgens conclusie 46, waarbij de fosfolipide een fosfatidylcholine (PC) is.The method or kit of claim 46, wherein the phospholipid is a phosphatidylcholine (PC).

48. Werkwijze of kit volgens conclusie 47, waarbij de fosfatidylcholine (PC) is geselecteerd uit de groep die bestaat uit l,2-didecanoyl-sn-glycero-3-fosfocholine (DPPC), 1,2-diërucoyl-sn-glycero-3-fosfocholine (DEPC), l,2-dilinoleoyl-sn-glycero-3-fosfocholineA method or kit according to claim 47, wherein the phosphatidylcholine (PC) is selected from the group consisting of 1,2-didecanoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-dielecoyl-sn-glycero 3-phosphocholine (DEPC), 1,2-dilinoleoyl-sn-glycero-3-phosphocholine

(DLOPC), l,2-dilauroyl-sn-glycero-3-fosfocholine (DLPC), 1,2-dimyristoyl-sn-glycero-3-fosfocholine (DMPC), l,2-distearoyl-sn-glycero-3-fosfocholine (DSPC), 1-myristoyl-2-palmitoyl-sn-glycero-3-fosfocholine (MPPC), l-myristoyl-2-stearoyl-sn-glycero-3-fosfocholine (MSPC), l-palmitoyl-2-myristoyl-sn-glycero-3-fosfocholine (PMPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-fosfocholine (POPC), l-palmitoyl-2-stearoyl-sn-glycero-3-fosfocholine (PSPC), l-stearoyl-2-myristoyl-sn-glycero-3-fosfocholine (SMPC), l-stearoyl-2-oleoyl-sn-glycero-3-fosfocholine (SOPC), l-stearoyl-2-palmitoyl-sn-glycero-3-fosfocholine (SPPC), ei-fosfatidylcholine (EPC), soja-PC, hydro-soja-PC (HSPC), hersen-PC, hart-PC, lever-PC, of welke combinatie dan ook van de voorgaande.(DLOPC), 1,2-dilauroyl-sn-glycero-3-phosphocholine (DLPC), 1,2-dimyristoyl-sn-glycero-3-phosphocholine (DMPC), 1,2-distearoyl-sn-glycero-3 phosphocholine (DSPC), 1-myristoyl-2-palmitoyl-sn-glycero-3-phosphocholine (MPPC), 1-myristoyl-2-stearoyl-sn-glycero-3-phosphocholine (MSPC), 1-palmitoyl-2-myristoyl -sn-glycero-3-phosphocholine (PMPC), 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1-palmitoyl-2-stearoyl-sn-glycero-3-phosphocholine (PSPC), 1-stearoyl-2-myristoyl-sn-glycero-3-phosphocholine (SMPC), 1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine (SOPC), 1-stearoyl-2-palmitoyl-sn-glycero 3-phosphocholine (SPPC), egg phosphatidylcholine (EPC), soy PC, hydro soy PC (HSPC), brain PC, heart PC, liver PC, or any combination of the foregoing.

49. Werkwijze of kit volgens conclusie 48, waarbij de fosfolipide 1,2-distearoyl-sn-glycero-3-fosfocholine (DSPC) is.The method or kit of claim 48, wherein the phospholipid is 1,2-distearoyl-sn-glycero-3-phosphocholine (DSPC).